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Abstract
Alpha-thalassemia X-linked mental retardation (ATR-X) syndrome is a rare genetic disorder
associated with severe developmental delay, mental retardation and craniofacial
dysmorphism. This syndrome is caused by mutations in the ATRX gene which encodes a
member of the SWI/SNF family of chromatin remodeling proteins. ATR-X patients exhibit
dwarfism and skeletal defects, including hand and foot deformities. I hypothesized that the
skeletal deformities in ATR-X syndrome are due to a direct role of ATRX in the
development of the skeleton. My objective was to characterise skeletal phenotypes observed
in three animal models conditionally deficient for ATRX in different skeletal tissues. Mice
lacking the Atrx gene in forelimb mesenchyme, cartilage, or bone were generated using the
Cre-lox system with Cre-recombinase under control of Prx1, Col2a1 or Col1a2 promoters,
respectively. Mice lacking ATRX in cartilage or bone displayed limited skeletal phenotypes
and did not recapitulate the defects seen in ATR-X syndrome. Loss of ATRX protein earlier
during limb development lead to shortening of the distal phalanges which correlated with
increased DNA damage and apoptotic cell death in the mesenchyme of developing digits.
This phenotype resembles brachydactyly in human ATR-X syndrome patients and suggests
that ATRX is involved in maintaining genome integrity in limb tissue. Aging mice lacking
ATRX in skeletal tissues did not show any increased susceptibility to osteoarthritis. In
summary, this study suggests that skeleton-intrinsic roles of ATRX are responsible for some
but

not

all

of

the

skeletal

deformities

ii

observed

in

ATR-X

syndrome.
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Chapter 1

1

Introduction
1.1

1.1.1

ATRX
ATR-X Syndrome

ATR-X Syndrome (Alpha-Thalassemia Mental Retardation, X-linked) is an X-linked
human disorder associated with severe psychomotor and mental retardation, characteristic
facial features, urogenital abnormalities, skeletal deformities, and alpha-thalassemia
(MIM# 301040) (Figure1-1) (Gibbons et al., 1995a). Patients present with global
developmental delay, learning problems, limited speech, and mental retardation (Gibbons
et al., 1995b). One original diagnostic tool used to define ATR-X syndrome was the
presence of a type of anemia, called α-thalassemia, which is caused by a lack of alphaglobin expression and results in β-globin inclusions in peripheral red blood cells
(Gibbons, 2006). These tetrameric inclusions of β-globin lead to a non-functional and
unstable form of haemoglobin that precipitates as haemoglobin H (HbH) tetramers in
older red cell populations (Higgs et al., 2009). Not all cases of ATR-X syndrome present
with HbH inclusions, although there may still be a down-regulation of α-globin
expression [Reviewed in (Gibbons, 2006)].
Characteristic facial features such as epicanthic folds, flat nasal bridge, small upturned
nose, and midface hypoplasia are seen in 94% of patients, and 66% of patients display
dwarfism (Gibbons et al., 2000a). ATR-X syndrome is rare, with just over 200 cases
reported, and there is limited availability of patient samples for study. Almost all affected
patients are male (XY karyotype) due to the X-linked nature of the disease (Gibbons et
al., 2008). Female carriers are unaffected with normal intellect and physical appearance
due to the skewed pattern of X-inactivation favouring silencing of the mutant allele
(Gibbons et al., 1992).
ATR-X syndrome bears similarity to other X-linked mental retardation syndromes,
described together as 'X-linked mental retardation-hypotonic facies syndromes' (MIM:
#309580). These syndromes include Carpenter-Waziri, Holmes-Gang, Juberg-Marsidi,
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Thirteen year-old boy with ATR-X syndrome showing the
typical facial appearance.

Figure 1-1 Molecular clinical spectrum of ATR-X syndrome
Reproduced with permission from: Gibbons et al. (2000) Am. J. Med. Genet. (Semin.
Med. Genet.) 97:204–212
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and Smith-Fineman-Myers syndromes and X-linked mental retardation with spastic
paraplegia (Abidi et al., 1999; Abidi et al., 2005; Lossi et al., 1999; Stevenson et al.,
2000; Villard et al., 2000; Villard et al., 1996). Studies have revealed that some of these
syndromes can be considered ATR-X syndrome, but absence of HbH inclusions excluded
them from the initial diagnosis. The presence of these inclusions is variable even between
ATR-X cases with the same mutation. A common 736C>T mutation seen in 32 cases of
ATR-X syndrome presents with varying frequency of HbH inclusions, ranging from 0 to
14% (Gibbons, 2006). This variability between identical mutations leads to difficulties in
making phenotype/genotype correlations and suggests the role for ATRX in α-globin
expression differs between patients.

1.1.2

ATRX Gene and Protein

The remodeling of chromatin influences the packaging and accessibility of DNA within
nucleosomes. While nucleosomes themselves are structurally stable, nucleosome
modifying and remodeling complexes confer specific properties to the chromatin by
modifying epigenetic marks on particular histones [Reviewed in (Saha et al., 2006)]. In
eukaryotes, there are at least five families of chromatin remodeling proteins; SWI/SNF,
ISWI, NURD/Mi-2/CHD, INO80 and SWR1 (Saha et al., 2006). SWI/SNF proteins exist
in large nucleosome remodeling complexes with evolutionarily distinct subfamilies and
functions (Carlson et al., 1994; Eisen et al., 1995). Purified SWI/SNF complexes directly
interact with nucleosomal DNA and enhance transcription by the hydrolysis of ATP to
open the chromatin or increase accessibility (Cote et al., 1994). SNF2 proteins utilize
ATP hydrolysis to power molecular motors that alter interactions between nucleic acids
and proteins to affect DNA wrapping around the nucleosome (Clapier et al., 2009). This
unwrapping function allows SWI/SNF complexes to disrupt the arrangement of
nucleosomes and thereby regulate gene transcription by altering DNA accessibility
(Peterson et al., 2000). SWI/SNF complexes can also alter chromatin structure through
nucleic acid twisting to generate superhelical torsion, which distorts helices and alters
the local chromatin topology (Havas et al., 2000). Complexes containing these proteins
play roles in transcriptional regulation, DNA repair, and regulation of
recombination [Reviewed in (Allard et al., 2004)].

mitotic
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ATR-X syndrome is caused by mutations in the ATRX gene (Gibbons et al., 1997;
Gibbons et al., 1995b). ATRX is located on the X-chromosome, is composed of 36 exons
spanning over 300 kilobases (kb), and encodes a potential protein of 2492 amino acids
(Villard et al., 1997). An alternative splicing event involving exon 11 generates a shorter
protein, ATRXt, which lacks the C-terminal domains (Garrick et al., 2004; Villard et al.,
1997). Comparative genetic analysis between mouse Atrx and human ATRX shows a high
degree (85% overall identity) of homology and the mouse and human proteins have a
similar weight of 280 kDa (Picketts et al., 1998). Conservation between human and
mouse ATRX is highest within two conserved functional motifs which code for a Plant
Homeo Domain (PHD)-like zinc finger at the N-terminus and a catalytic ATPase domain
at the C-terminus (Figure 1-2) (Gibbons et al., 1997; Picketts et al., 1996; Picketts et al.,
1998). Mutations to the regions coding these domains can cause a reduction in protein
levels or diminish enzymatic function (Gibbons et al., 1995b; Picketts et al., 1996).
Furthermore, most disease-causing mutations identified in ATR-X patients are within
these conserved domains, confirming their requirement in normal development (Gibbons
et al., 2008). Complete loss of function is not observed in ATR-X syndrome, which
suggests complete loss of ATRX protein in humans is lethal (Gibbons et al., 1995b;
Picketts et al., 1996).

1.1.3
1.1.3.1

Functions of ATRX
Biochemical Functions of ATRX

A number of ATR-X mutations are concentrated in the PHD-like domain, suggesting this
region has an important functional role in vivo (Gibbons et al., 1997). The PHD-like zinc
finger has homology with the DNMT3 family of DNA methytransferases, leading to the
specific name ATRX-DNMT3-DNMT3L (ADD) domain (Aapola et al., 2000; Argentaro
et al., 2007; Xie et al., 1999). Characteristic of a protein containing an ADD domain,
ATRX appears to influence methylation of DNA but

5

Figure 1-2 Major domains of the ATRX protein
Major domains of the full length ATRX and truncated ATRXt protein: the PHD zinc
finger-like domain (ADD), SNF2 chromatin remodeling domain (Helicase domain), the P
box a (P), and glutamine-rich region (Q).
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whether this is a direct effect or not is unknown. Specifically, EBV-transformed
lymphocytes from ATR-X patients demonstrate alterations to the methylation pattern of
ribosomal DNA (rDNA), Y chromosome-specific and subtelomeric repeats of DNA
(Gibbons et al., 2000b). The C-terminal catalytic domain of ATRX has seven conserved
collinear helicase domains, and is homologous to the RAD54-like subfamily of SNF2
family of chromatin remodeling proteins (Flaus et al., 2006; Picketts et al., 1996).
RAD54 is a DNA translocase that plays an important role in DNA strand exchange for
the recombinational DNA repair (RAD52) pathway (Shah et al., 2010; Solinger et al.,
2002).
The conservation of important functional domains of ATRX suggests it has chromatinremodeling functions (Aasland et al., 1995). SNF2 proteins are involved in DNA
replication, ATP-dependent chromatin remodeling, and processing of DNA damage
(Chai et al., 2005; Cote et al., 1994; Flanagan et al., 1999). In vitro studies of
recombinant ATRX have demonstrated that the SWI/SNF domain possesses ATPase
activity that is stimulated by mononucleosomes (Tang et al., 2004). ATP hydrolysis is
also required for the translocase activity of ATRX, allowing it to unwind a third strand of
DNA wrapped around a double helix, in what is known as a triple-helix displacement
assay (Mitson et al., 2011a; Xue et al., 2003). Some mutations to the SNF2 domain of
ATRX weaken its ability to mechanically slide along double-stranded DNA in vitro, an
activity termed DNA translocation (Mitson et al., 2011b).
Evidence suggests that a complex containing ATRX has a role in chromatin assembly at
tandem repeat regions, including G-rich regions and G-quadruplex structures (Law et al.,
2010). A G-quadruplex is a structure that occurs in single-stranded G-rich DNA, where
the DNA self-associates in a four-stranded complex of guanines binding to each other
(Sen et al., 1988). These structures are predicted to occur frequently in areas of the
genome targeted by ATRX, including telomeres, rDNA, G-rich minisatellites, and CpGrich promoters (Law et al., 2010). The binding of ATRX to G-quadruplex structures may
be a mechanism by which ATRX influences the expression of α-globin in erythroid cells
(Law et al., 2010). It is predicted that ATRX recognizes unusual and difficult-to-replicate
DNA configurations, like the G-quadruplex, and converts them into normal forms of
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DNA through incorporation of histone variants (Law et al., 2010; Watson et al., 2013).
Stabilizing G-quadruplexes with the ligand telomestatin exacerbated the DNA damage
phenotype and decreased the survival of ATRX-null mouse neuroprogenitors, confirming
a requirement for ATRX in replication through these structures (Watson et al., 2013).
ATRX may interact with heterochromatin through direct contact with DNA. Synthetic
peptides of the C-rich zinc finger domains of ATRX were shown to effectively associate
with double-stranded DNA in a gel-shift assay (Cardoso et al., 2000). ATRX can also
bind directly to G-quadruplexes in vitro (Law et al., 2010). Together, these studies
suggest another mechanism by which ATRX can influence DNA, and also target
repetitive regions.

1.1.3.2

Transcriptional Regulation

Considering the biochemical functions of ATRX, it is expected to play significant roles in
DNA recombination, DNA repair, and regulation of transcription. When mutations
reduce the function of ATRX in humans, expression levels of α-globin may be reduced
(Gibbons et al., 1995b). This observation provides a genetic and functional component
linking ATRX mutations with the down-regulation of α-globin gene expression leading to
alpha thalassemia (Gibbons et al., 1995b). Since this initial observation, ATRX has been
shown to affect the expression of other genes. Microarray analysis of gene expression
within the embryonic forebrains of mice which lacked ATRX beginning at E8.5 showed
changes in the expression of ancestral pseudoautosomal genes (Levy et al., 2008). Genes
with significantly altered expression in the forebrains of E13.5 Atrx-deficient mice also
include genes required for brain development such as Gbx2 and Neurod4 (Levy et al.,
2008). ATRX-deficient postnatal mouse forebrain also demonstrates defective repression
of a number of imprinted genes, including H19 and Igf2 (Kernohan et al., 2010).
Expression analysis on ATR-X patient peripheral blood mononuclear cells has shown a
significant decrease in the expression of GTPase regulator associated with the focal
adhesion kinase (GRAF1) and also confirmed a decrease in α-globin expression in some
cases (Barresi et al., 2010). Therefore, ATRX is predicted to play a role in controlling the
regulation of numerous genes.
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A role of ATRX in transcriptional control is also suggested by the putative association
with the human homolog of the polycomb protein Drosophila enhancer of zeste 2 (EZH2)
(Cardoso et al., 1998). Using a yeast-two hybrid screen between various heterochromatinassociated proteins and ATRX, the C-terminal SET domain of EZH2 was found to
interact with ATRX (Cardoso et al., 1998). This interaction may play a role in forming
repressive complexes, and regulating homeotic gene expression in a developmental or
tissue-specific context [Reviewed in (Mahmoudi et al., 2001)]. Yeast-two hybrid screens
have also demonstrated a possible interaction between SWI/SNF domains and murine
heterochromatin protein 1α (HP1α), which has been verified by coimmunofluorescence
between ATRX and HP1α (Le Douarin et al., 1996; McDowell et al., 1999). This
interaction was confirmed by co-immunoprecipitation in human cells, and has been
assigned to a putative PxVxL motif (LYVKL) which interacts with the HP1α
chromoshadow domain (Berube et al., 2000; Lechner et al., 2005). ATRX has also been
predicted to associate with histone deacetylase 4 (HDAC4) through a yeast two-hybrid
screen using an N-terminal fragment of HDAC4 (Wang et al., 2005).
Wide-scale genome studies have been conducted to identify sequences for ATRX binding
in ES cells (Law et al., 2010). ATRX predominantly localizes to GC-rich sequences,
including CpG islands, repetitive sequences, pericentromeric heterochromatin and
telomeres. Among these targets are several sites where ATRX binds to directly influence
gene expression, including the Rhox5 promoter in Sertoli cells, the H19 imprinting
control region in brain, and VNTR repeats near α-globin (Bagheri-Fam et al., 2011;
Kernohan et al., 2010; Law et al., 2010). The localisation of ATRX to ancestral
pseudoautosomal regions of the genome is also speculated to be due to the repetitive
nature of sequences surrounding these regions (Levy et al., 2008). Like tandem repeats,
pseudoautosomal genes are rich in

repetitive sequences and suggest a common

epigenetic environment for ATRX to control expression of genes (Levy et al., 2008).
Finally, ATRX has been reported to associate with the inactive X-chromosome during
embryonic stem cell differentiation and X-inactivation (Baumann et al., 2009).
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1.1.3.3

Protein Interactions of ATRX

SWI/SNF chromatin remodeling complexes are large and contain multiple subunits, so
ATRX function may be elucidated by identifying other members of the complex. Early
studies identified an interaction between ATRX and DAXX (Death-associated protein
6), a death domain associated protein involved in transcription and cell cycle regulation
(Ishov et al., 2004; Tang et al., 2004; Xue et al., 2003). ATRX and DAXX reside in
promyelocytic leukaemia (PML) bodies, at heterochromatin, and at telomeres (Goldberg
et al., 2010; Tang et al., 2004; Xue et al., 2003). Immunopurification of DAXX from
HeLa cell nuclear extract causes most of the ATRX protein to purify out of the extract at
near equimolar amounts (Xue et al., 2003). This interaction between ATRX and DAXX
was confirmed by immunoprecipitation in human 293T cells extracts, and mapped to the
NH2-terminal PAH domains of DAXX and the middle region of ATRX (Tang et al.,
2004).
Recombinant DAXX has been shown to preferentially bind Histone 3.3 (H3.3) and
deposit histone tetramers onto DNA (Drané et al., 2010). This assembly complex
includes ATRX, suggesting that ATRX may assist in depositing histones, specifically
H3.3 (Drané et al., 2010). ATRX is required for repression of telomeric RNA and
maintenance of H3.3 localisation at the telomeres in mouse ES cells (Goldberg et al.,
2010). ATRX co-localizes with telomeric H3.3, and this localization is lost when the K4
residue of H3.3 is mutated (Wong et al., 2010). When this co-localization is perturbed by
RNAi depletion of ATRX, mouse ES cells display reduced HP1α incorporation and have
telomere dysfunctions (Wong et al., 2010). Telomere dysfunction phenotypes can be
caused by loss of specific post-translational histone modifications such as trimethylation
at lysine 9 of H3 (H3K9me3) and trimethylation at lysine 20 of H4 (H4K20me3) and can
lead to chromosomal instability and aberrantly increased telomere length (Garcia-Cao et
al., 2004; Wong et al., 2009). Functionally, ATRX has been demonstrated to read
methylation states of histone tail peptides. The ADD domain of ATRX can bind to H3
tails, with a specificity for H3K9me3 and unmethylated lysine 4 (H3K4me0) (Dhayalan
et al., 2011).
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An interaction between ATRX and the methyl-CPG binding protein MeCP2 has been
identified in which MeCP2 associates directly with the helicase domain of ATRX and
recruits it to heterochromatin (Nan et al., 2007). Mutations in the MECP2 gene cause the
progressive neurodevelopmental disorder Rett syndrome, which bears some similarities
to ATR-X syndrome (Amir et al., 1999; Dotti et al., 2002). Rett syndrome is
characterized by normal development until 6-18 months of age, then a gradual loss of
speech and purposeful hand use (Amir et al., 1999). Patients develop microcephaly,
seizures, autism, ataxia, intermittent hyperventilation, and stereotypic repetitive hand
movement (Amir et al., 1999). Mecp2 mutation or deficiency in mouse perturbs its
interaction with ATRX, and leads to disrupted localization of ATRX to pericentromeric
heterochromatin (Baker et al., 2013; Nan et al., 2007).

In a mouse model of Rett

syndrome, loss of an AT-hook domain of MeCP2 abrogates recruitment of ATRX and
was the difference between death or survival of the animals, suggesting this interaction
might be important (Baker et al., 2013). Furthermore, it was also found that the ATRXMeCP2 complex localizes to imprinted genes, where it also associates with the cohesin
complex (Kernohan et al., 2010).

1.1.3.4

ATRX and the Cell Cycle

During interphase, ATRX is observed by immunofluorescence to have a speckled pattern
within the nucleus and concentrate at sites of pericentromeric heterochromatin
(McDowell et al., 1999). The localisation of ATRX relative to the chromatin is altered
throughout the cell cycle in human cancer cell lines (Berube et al., 2000). Using indirect
immunofluorescence and cell fractionation, ATRX was shown to localise with nuclear
matrix during interphase, but associate with condensed chromatin at the beginning of Mphase (Berube et al., 2000).

During mitosis, ATRX becomes phosphorylated and

associates with HP1α, binding centromeric DNA at metaphase and anaphase, and having
a less distinct association pattern during telophase (Berube et al., 2000). These data
suggest that ATRX moves throughout the cell in a cell-cycle dependant fashion. Loss of
ATRX in myoblasts leads to changes in expression of cell cycle genes and aberrant cell
cycle gene regulation (Huh et al., 2012). Similarly, cell cycle progression is aberrant in
ATRX-deficient Sertoli cells, which demonstrate a 38% increase in phospho-histone H3
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(PH3), a marker of late G2 phase and mitosis compared to controls (Bagheri-Fam et al.,
2011). A requirement for ATRX throughout the cell cycle has also been demonstrated in
HeLa cells, where depletion of ATRX by siRNA leads to chromosome cohesion and
congression defects during mitosis (Ritchie et al., 2008). Chromosome segregation and
meiotic spindle formation defects are also seen in mouse oocytes depleted of ATRX (De
La Fuente et al., 2004).

1.1.3.5

ATRX and Genomic Stability

Depletion studies of ATRX have demonstrated that ATRX loss leads to increased
replicative stress at telomeres (Huh et al., 2012; Watson et al., 2013; Wong et al., 2010).
Recently, important roles for ATRX in genomic integrity have been demonstrated in
oocytes, muscle, tumour cell lines, and brain (Baumann et al., 2010; Huh et al., 2012;
Lovejoy et al., 2012; Watson et al., 2013). When ATRX is depleted in cells, chromatid
defects are observed including lobulated nuclei, formation of micronuclei, and chromatin
bridges (Baumann et al., 2010; De La Fuente et al., 2004; Ritchie et al., 2008). These
studies present an important role for ATRX in mitotic cell division and maintenance of
genomic integrity.
The association of ATRX to the telomeres of mouse ES cells during interphase has been
linked to incorporation of histone H3.3, which is required for telomere function (Wong et
al., 2010). Telomere dysfunction has been observed in cases of paediatric glioblastoma,
where mutations in ATRX or DAXX were associated with alternative lengthening of
telomeres (ALT) (Heaphy et al., 2011; Lovejoy et al., 2012; Schwartzentruber et al.,
2012). ALT is a telomerase-independent process in which telomere recombination is used
to counteract telomere attrition [Reviewed in (Cesare et al., 2010)]. ALT is associated
with poorer outcomes in cancer, as normal telomere attrition is associated with telomere
shortening and eventual senescence (Reddel, 2000). In panels of ALT cell lines, loss of
ATRX was frequently found to be a predictor of ALT, as well as genome rearrangements,
micronucleation, defects in cell cycle, and defects in double-strand break repair (Lovejoy
et al., 2012). Since there is a requirement for ATRX to deposit HP1α and H3.3 at
telomeres, loss of ATRX would alter protein loading at the telomeres and lead to
telomere dysfunction (Lovejoy et al., 2012; Wong et al., 2010).

This contribution of
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ATRX to proper telomere function prevents ALT in cancer cells, demonstrating an
important role for ATRX in maintaining normal telomere integrity (Lovejoy et al., 2012).

1.1.3.6

Mouse Models of ATR-X Syndrome

Gene knockout strategies have been used to understand functional roles of genes in the
mouse and other organisms; however, conventional gene knockouts can lead to
embryonic lethality and are not ideal for examining development of a specific tissue
[Reviewed in (Zhang et al., 2012)]. The prokaryotic cre-lox site-specific recombination
system has been used in eukaryotes

to drive both site and time-specific gene

recombination (Sauer, 1987). Cre is a viral protein which can promote recombination of
loxP sites, which is now used to generate various animal models (Sternberg et al., 1981;
Zhang et al., 2012). This system allows the specific manipulation of DNA based on the
location and arrangement of two loxP sites (Hoess et al., 1982). When two loxP sites are
arranged in the same direction on a strand of DNA, the activity of cre in a tissue of
interest will excise the targeted sequences between these sites [Reviewed in (Zhang et al.,
2012)].
Studies removing Atrx in mouse ES cells indicate that Atrx may be required for normal
ES cell growth and expansion (Garrick et al., 2006). To bypass these effects and identify
roles for Atrx in later-stage tissues, conditional alteration of Atrx using the Cre-loxP
system has revealed specific roles for Atrx in the development of various tissues.
Conditional deletion of Atrx at the morula stage using a ubiquitous GATA1-cre transgene
has demonstrated that Atrx is required during early embryogenesis, as AtrxNull embryos
demonstrate a dramatically reduced trophectoderm layer and growth restriction (Garrick
et al., 2006). Conditional inactivation in the forebrain using Foxg1-cre leads to reduced
brain size and excessive apoptosis (Bérubé et al., 2005). Loss of cells was also observed
in the retinas of mice depleted of Atrx using a Pax6-cre system (Medina et al., 2009).
Atrx has been conditionally inactivated in the testes of mice with an AMH-cre, leading to
smaller testes with defects in cell cycle and spermatogenesis (Bagheri-Fam et al., 2011).
These methods compliment micro-injection and siRNA methods, and provide a growing
body of tissue-specific knockout animals that illustrate specific and direct properties of
Atrx in mouse development.
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Numerous knockout studies in mice have demonstrated a DNA-damage or cell-death
phenotype in tissues of these animals (Bagheri-Fam et al., 2011; Bérubé et al., 2005; Huh
et al., 2012; Watson et al., 2013). In vitro studies have established that some ATRXdeficient cells are more sensitive to DNA damaging agents, and more susceptible to cell
death during proliferation (Conte et al., 2012; Watson et al., 2013). Cell death can be
prevented by deleting the tumor suppressor protein p53 concomitantly with ATRX,
although this does not completely rescue the phenotype of ATRX loss in the brain (Seah
et al., 2008). Loss of ATRX in macrophages sensitizes them to DNA-damaging agents
though the p53 pathway (Conte et al., 2012). Furthermore, when cell death of
neuroprogenitors is prevented by p53 deletion, DNA damage continues to accumulate in
these cells (Watson et al., 2013). Thus, loss of ATRX leads to DNA-damage, p53mediated cell death, and eventual hypocellularity in some tissues including forebrain,
muscle, and testes (Bérubé, Mangelsdorf et al. 2005; Huh, Price O'Dea et al. 2012;
Bagheri-Fam, Argentaro et al. 2011).
Skeletal abnormalities in ATR-X patients range from relatively mild to severe. One-third
of ATR-X patients have spinal deformities such as kyphosis or scoliosis (Gibbons et al.,
1995a). The majority also have retarded physical and osseous development (delayed
bone age), demonstrating fundamental problems in growth and bone maturity (Gibbons et
al., 1995a). For some patients these skeletal abnormalities are apparent at birth, for others
they manifest later in life around the time of the pubertal growth spurt (Gibbons et al.,
2000a). Finally, hand and foot deformities are common, including fingers with fixed
flexion deformities, clinodactyly, brachydactyly, tapering fingers, overlapping digits,
syndactlyly of toes, and bifid thumb (Gibbons et al., 1995a).

1.2

Development of the Appendicular Skeleton

The skeletal defects seen in ATR-X syndrome suggest an important role for ATRX in
proper development of the skeleton. Studies of ATRX protein have revealed functions in
DNA and chromatin binding, gene expression control, and maintenance of genomic
integrity. ATRX participates in complexes with other important gene-regulating proteins.
Furthermore, studies continue to reveal pathologies in ATRX-depleted tissues and
organs, which may extend to the developing skeleton.
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Mouse limb development begins with the formation of the limb bud, an outgrowth of
undifferentiated mesenchyme cells from the body wall of the developing embryo. This
outgrowth is controlled by fibroblast growth factor (FGF) signaling from the apical
ectodermal ridge (AER) which directs growth in a proximodistal axis (shoulder to digits)
(Niswander et al., 1993). Patterning is also directed by the zone of polarizing activity
(ZPA) which directs positional information across the limb bud mesenchyme (Wolpert,
1969). This ZPA secretes molecules required to specify the anterio-posterior axis and
perturbations to this zone lead to duplication or loss of structures in the limb (Tickle,
1981). One of the most important molecules produced specifically by the ZPA is sonic
hedgehog (SHH), which is required for polarizing limb tissue and activation of Hox genes
(Riddle et al., 1993).
Once these axes of limb outgrowth and patterning are established, the limb undergoes a
SHH-directed proliferative expansion (Zhu et al., 2008). This expansion provides the
necessary population of cells to contribute to all subsequent limb structures. Inhibition of
early proliferation leads to an overall reduction in the size of skeletal elements in the limb
(Ota et al., 2007). When SHH is perturbed, there can be defects in both the type and
number of digits formed out of the limb bud (Tickle, 2006). Positional digit identity is
determined by SHH and its transcriptional effectors GLI1, GLI2, and GLI3, and studies
altering these effects have demonstrated loss of digits (Zeller, 2004). Digits are first
formed as precartilaginous condensations within the limb bud, where mesenchymal cells
are recruited to the site of digit formation and begin producing cartilage-specific
collagens and proteoglycans (Hall et al., 1995). Following establishment of the
unsegmented cartilage anlagen, future joints are established at sites where chondrocytes
flatten and become non-chondrogenic (Craig et al., 1987). This joint interzone contributes
to the formation of structures of the synovial joint, including the joint capsule, synovial
fluid, and articular cartilage (Francis-West et al., 1999). Distal FGF signaling from the
AER drives elongation of the digit, determining both the final length of the phalanges and
their number (Sanz-Ezquerro et al., 2003).
The long bones of the mammalian skeleton develop through a process known as
endochondral ossification. In this process, templates of bones are laid down as
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condensations of mesenchymal cells, which differentiate into chondrocytes and form
precursors to the bones (Figure 1-3) [Reviewed in (Kronenberg, 2003)]. In the case of
digit bones, as well as the long bones of the appendicular skeleton, the cartilage template
grows longitudinally and become ossified into bone. The differentiated chondrocytes are
found in three populations that are fundamental to promoting bone growth: resting,
proliferating, and hypertrophic (Hunziker, 1994). The proliferating cells continually
replenish a population of cells that undergo terminal differentiation and hypertrophy,
growing in size and producing a collagen matrix, with proliferation and hypertrophy both
contributing to longitudinal growth (Noonan et al., 1998). This highly-regulated process
determines the growth rate and final size of the bone (Breur et al., 1991). The center of
the bone becomes invaded by blood vessels, and the hypertrophic cartilage cells die
through apoptosis to be replaced by osteoblasts carried in from the bone collar [Reviewed
in (Ducy et al., 2000)].
Osteoblasts are mesenchymal cells, which are only distinguishable from other types of
fibroblasts by virtue of their ability to synthesise and deposit extracellular matrix as part
of bone and other mineralised tissues (Ducy et al., 2000). Expression and DNA binding
activity of Runx2 increase as osteoblasts mature, and this maturation is associated with
production of proteins required to produce a mineralised matrix (Banerjee et al., 2001;
Ducy et al., 2000).This matrix is composed primarily of type I collagen with other noncollagenous proteins responsible for induction or regulation of mineralisation [Reviewed
in (Robey et al., 1993)]. Bone formation and mineralization by the osteoblast and bone
remodeling by the osteoclast continue throughout life, maintaining mineral balance and
bone physiology (Ducy et al., 2000). Perturbations in the differentiation to any of the
three cell types (chondrocyte, osteoblast, or osteoclast) lead to numerous skeletal
pathologies and defects in skeletal development, including dwarfisms and brachydactyly
(Stricker et al., 2011).
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Figure 1-3 Endochondral ossification.
During endochondral ossification, chondrocytes form a model of the later bones and form
zones of resting, proliferating, and hypertrophic chondrocytes. Hypertrophic cartilage is
invaded by blood vessels and ultimately replaced by bone tissue and bone marrow in the
primary ossification center. Postnatally, a similar process results in the formation of the
secondary ossification center, and the growth plate forms between primary and secondary
ossification center. In humans, the growth plates close and the primary and secondary
ossification centers fuse at the end of puberty.

Reproduced with permission from: Solomon et al. (2008) Birth Defects Research Part C:
Embryo Today: Reviews. 82 (3): 123-130
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1.3

Genetic Origins of Brachydactyly

Brachydactyly is a medical condition in which digit bones are shortened relative to other
long bones in the body (Stricker et al., 2011). It can be an isolated heritable trait, but is
also seen in association with other phenotypes in various malformation syndromes
(Temtamy et al., 2008). The similarities between ATR-X syndrome and other
brachydactyly syndromes suggest ATRX may control one or several pathways required
for proper development of the skeleton and specifically the hands and feet.

1.3.1

Forms of Brachydactyly

Forms of brachydactyly are classified into ten main types: four types of brachydactyly
type A (Subdivided into BDA1, BDA2, BDA3, BDA4), brachydactyly types B, C, D, E,
Sugarman type brachydactyly and Kirner deformity (Temtamy et al., 2008). The type A
brachydactylies are typified by shortening of the middle phalanges, with subtypes
defining specific clinical descriptions (Temtamy et al., 2008).
Brachydactyly type A1 has been recapitulated in mice using the BDA1 mouse model,
which is carries a point mutation affecting the efficacy of Indian hedgehog (IHH). IHH is
a secreted ligand which functions in a graded fashion with its receptor patched [Reviewed
in (Varjosalo et al., 2008)]. The BDA mutation alters the range of IHH influence, as well
as its capacity to signal in the growing cartilage templates of the distal digits, specifically
phalange 2 (Gao et al., 2009). IHH mutations in humans lead to both brachydactyly and
short stature, as well as generalized skeletal deformities and occasional developmental
delay (Kirkpatrick et al., 2003; McCready et al., 2002).
Similar to the type A1 brachydactyly seen in the BDA1 mouse and human cases of IHH
mutations, Brachydactyly type B is characterized by absence or hypoplasia of all distal
phalanges (Temtamy et al., 2008). This form of brachydactyly can be due to mutations in
ROR2, such as in ROR2-related Robinow syndrome, which is associated with growth
retardation, limb shortening and brachydactyly in humans, and also genital abnormalities
and developmental delay in some cases (Afzal et al., 2000; Wadia et al., 1978). ROR2
encodes a tyrosine kinase receptor and can affect chondrogenesis by indirectly inhibiting
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GDF5 (TGF-beta superfamily member Growth/differentiation factor 5) signaling via
canonical and non-canonical WNT signaling (Maeda et al., 2012; Sammar et al., 2004).
Defects in GDF5 signaling also lead to defects in the hand and foot. Mutations in Gdf5 in
mice alter bone length and patterning of the feet, with disorganization of the phalanges
(Storm et al., 1994). Over-expression of wild-type or mutant GDF5 in developing chick
limbs influences BMP signaling and causes joint fusions (Seemann et al., 2005). Humans
heterozygous for GDF5 mutations present with segmentation defects of the digits,
underdevelopment of phalangeal bones, and in some cases, short stature (Everman et al.,
2002).
Brachydactyly type C manifests as shortening of proximal hand bones, characteristically
all the metacarpals with greatest shortening in the thumb (Burgess, 2001). This condition
is rare, and associated with GDF5 mutations much like Brachydactyly type B (Seo et al.,
2013). Brachydactyly type D is a milder form of hand deformity, consisting of
abnormally short thumbs with otherwise normal hands (Gray et al., 1984). This syndrome
is associated with mutations in the human HOXD13 gene, which is also associated with
the more severe Brachydactyly type E (Johnson et al., 2003). Brachydactyly type E
comprises of shortening of one or more metacarpals or metatarsals (Johnson et al., 2003).
Genetic syndromes such as Rubinstein-Taybi, Saethre-Chotzen, and Turner syndrome
can also present with brachydactyly type D or E (Johnson et al., 2003). Many of these
syndromes involve genes are highly conserved with roles in development, and
demonstrate that many defects in development can manifest with specific deformities of
the hands and feet.

1.4
Genetic Origins of Dwarfism and Skeletal
Deformities
Dwarfism and skeletal deformities are medical conditions that can originate from genetic
disorders affecting the skeleton. Many of these syndromes originate from defects in
regulation of growth plate chondrocytes by transcription factors. One of the most
important factors is the sex-determining region Y-box 9 (SOX9), along with SOX family
of transcription factors SOX5 and SOX6, which are required to drive induction of
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cartilage from precursor cells (Ikeda et al., 2004). These proteins commit mesenchymal
cells towards chondrocytes, and promote expression of critical matrix genes such as
collagen types II, IX, and XI, and aggrecan (Han et al., 2008). Insufficiency SOX9 leads
to campomelic dysplasia, which presents as skeletal malformations including cleft palate
and short stature (Kwok et al., 1995).
Other short stature syndromes, such as Léri-Weill dyschondrosteosis and Langer
mesomelic dysplasia are caused by loss-of-function in the human SHOX (short stature
homeobox) gene (Belin et al., 1998; Clement-Jones et al., 2000; Shears et al., 1998; Zinn
et al., 2002). Many of these mutations affect the transcriptional activity of SHOX and
subsequently the normal cell cycle within the endochondral growth plate (Sabherwal et
al., 2004; Schneider et al., 2005).
The human SHOX2 gene shares evolutionary conservation with mouse Og12x (Shox2),
although rodents do not demonstrate any homologous genes to human SHOX (ClementJones et al., 2000). Human SHOX2 and mouse Shox2 possess similar functions in
transcriptional gene repression in vitro (Liu et al., 2011; Rao et al., 1997). Both the
mouse and human versions of SHOX2 are located on autosomal chromosome 3, while
human SHOX is located on the pseudoautosomal region of the sex chromosomes
(Blaschke et al., 1998; Rao et al., 1997; Semina et al., 1998). Mouse models of short
stature syndromes, generated by conditional deletion of Shox2 in the limbs, demonstrate
shortened proximal limb bones (Cobb et al., 2006; Yu et al., 2007).
Loss of SHOX2 in mice leads to defects in chondrocyte hypertrophy due to reduced
levels of RUNX2 (Cobb et al., 2006). Similar growth plate defects and long-bone
shortening due to failed progression of endochondral ossification are seen when Runx2 is
deleted in cartilage of developing mice (Chen et al., 2011). However, unlike Shox2
mutants which demonstrate shortening of specific stylopod elements, Runx2 and Runx3
loss of function in mice affects all endochondral bones (Yoshida et al., 2004).
Establishment and longitudinal expansion of the growth plate also requires proper
function of myocyte enhancer factor 2 (MEF2), which is involved in many facets of
normal development (McKinsey et al., 2002; Potthoff et al., 2007). MEF2C and MEF2D
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affect upstream regulation of Runx2 and influence hypertrophic differentiation in mouse
endochondral bones (Arnold et al., 2007). MEF2C levels are upregulated during
chondrocyte differentiation and required for collagen X promoter activity (James et al.,
2005; Stanton et al., 2004). MEF2C is also required for expression of the distal-less
homeobox proteins, Dlx5 and the related Dlx6, which are required for craniofacial and
skeletal development (Verzi et al., 2007). Mutations in DLX genes are associated with
split-hand/split-foot malformation and defects in axial limb outgrowth (Robledo et al.,
2002). Similar to SHOX, DLX5 and DLX6 are required for proper growth and
hypertrophy of the cartilage growth plate (Bendall et al., 2003; Chin et al., 2007; Ferrari
et al., 2002; Hsu et al., 2006); therefore, the endochondral growth plate is under tight
genetic regulation,

and genetic perturbations can cause dwarfisms and skeletal

deformities.

1.4.1

Chromatin Proteins Involved in Skeletal Development

Alterations in the function of chromatin-remodeling proteins can lead to severe skeletal
malformations (Alvarez-Saavedra et al., 2010; Young et al., 2005). This correlation holds
true for ATR-X syndrome, which is associated with loss of function of a SWI/SNF
chromatin remodeler and frequently presents with skeletal deformities (Gibbons et al.,
2000a). Although there are limited genotype-phenotype correlations between specific
mutations in ATRX and skeletal defects, severe disease conditions appear to be related to
mutations in the conserved functional domains of the protein (Gibbons et al., 2008).
These phenotypes have a high degree of overlap with many other syndromes related to
common

defects

of

chromatin

structure

or

modification.

Dysregulated

expression of Mecp2 in skeletal tissue of mice produces severe malformations, including
protrusion of the sternum and kyphosis (Alvarez-Saavedra et al., 2010). Animals overexpressing Mecp2 in skeletal tissues have shortened limbs and incomplete ossification,
possibly due to deregulation of Runx2 (Alvarez-Saavedra et al., 2010).
Rubinstein-Taybi syndrome (RTS), also known as broad thumb-hallux syndrome, is a
mental retardation syndrome with skeletal abnormalities including short stature and
deformities of the hands and feet (Rubinstein Jh, 1963). RTS bears pathologic similarities
to ATR-X syndrome, such as dysmorphic facial features and microcephaly, and can be
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caused by mutations in CREBBP (Bartsch et al., 2010; Lopez-Atalaya et al., 2012).
CREBBP is a cAMP response element-binding protein (CREB)-binding protein that can
acetylate histones H2B and H2A (Lopez-Atalaya et al., 2012). Post-translational
modifications to histones can affect their charge and function, leading to significant
changes in both chromatin structure and gene transcription [Reviewed in (Struhl, 1998)].
Haploinsufficiency of Crebbp in mice leads to defects in osteoclastogenesis and reduced
trabecular number, as well as patterning defects, delayed ossification, and brachydactyly
(Tanaka et al., 1997).
Another rare syndrome, Brachydactyly Mental Retardation Syndrome (BDMR), is caused
by deficiency of HDAC4 (Williams et al., 2010). HDAC4 enzymatically deacetylates
nucleosomal histones (Grozinger et al., 1999).

This syndrome, like many other

syndromes associated with chromatin-affecting proteins, presents with intellectual
disabilities and developmental delays, as well as craniofacial and skeletal abnormalities
including brachydactyly type E (Williams et al., 2010). In mice, Hdac4 is expressed in
prehypertrophic

chondrocytes

during

development

and

regulates

chondrocyte

hypertrophy through inhibition of Runx2 (Vega et al., 2004). Mice lacking Hdac4 display
dwarfism with premature ossification of developing bone and unrestrained transcriptional
activation of Mef2 and Runx2 (Vega et al., 2004).
Compound mouse mutants, lacking both Hdac4 and Mef2c, have a rescue of the
ossification defects indicating an important interaction between these factors (Arnold et
al., 2007). This direct function of HDACs regulating MEF2 activity has also been
demonstrated in myoblasts (Lu et al., 2000a; Lu et al., 2000b; Zhang et al., 2002).
Additionally, HDAC4 has been shown to interact directly with ATRX by yeast twohybrid assay (Wang et al., 2005), suggesting again that a common epigenetic theme may
be involved in chromatin remodeling and skeletal development.
Similarly to Brachydactyly Mental Retardation Syndrome, Cornelia de Lange syndrome
(CDLS) is a syndrome with craniofacial dysmorphia, hirsutism, missing or shortened
fingers, gastroesophageal dysfunction, growth retardation, neurodevelopmental delay,
and other physiological anomalies. This syndrome is caused by functional mutations in
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genes encoding members of the cohesin complex, including NIPBL, SMC3, and SMC1A
(Deardorff et al., 2007; Krantz et al., 2004; Tonkin et al., 2004). Mice hemizygous for
Nipbl have decreased body size, delayed embryonic ossification of both endochondral
and intramembranous bones, and reduced bone length (Kawauchi et al., 2009). Cohesin
subunits involved in CDLS interact with both MeCP2 and ATRX in the mouse brain invivo (Kernohan et al., 2010). Together, ATRX, MeCP2, and cohesin can co-localize to
imprinted regions such as H19/Igf2 and Gtl2/Dlk1, lending further evidence to the theory
that ATRX localizes to specific epigenetic environments (Kernohan et al., 2010). These
studies demonstrate an important requirement for chromatin remodeling, and in specific
SWI/SNF function, for proper initiation and gene expression in the development of the
skeleton.
Dominant negative mutations in the SWI/SNF subunit BRG1 reduce expression of the
important skeletal transcription factor Runx2 (Young et al., 2005). Brg1 is expressed in
cells of the developing mouse skeleton and in bone-forming osteoblasts (Young et al.,
2005). Dominant negative mutants of BRG1 SWI/SNF function block induction of
Alkaline Phosphatase (APase), a marker of osteoblast differentiation (Young et al.,
2005). This model demonstrates a direct requirement of chromatin remodeling complexes
in RUNX2-dependent skeletal gene expression.

1.4.2

Indirect Regulation of Bone Development

Many of the defects described in the aforementioned models are due to direct influences
of genes within the skeleton; however, the skeleton exists as part of a highly regulated
system of growth and development within the context of the entire body and must also be
regulated by more central and indirect methods. One important axis involved in
determining bone size and bone mineral density is the insulin-like growth factor (IGF)-I
axis [Reviewed in (Mohan et al., 2012)]. Levels of circulating IGF-1 are sensed by the
epiphyseal cartilage and controlled by neuroendocrine pathways in the brain, which
determines overall growth, body size, and lifespan (Hoshi et al., 2004; Kappeler et al.,
2008). This feedback system involves the thyroid, brain and skeleton, which regulate
endocrine homeostasis and maturation of the epiphyseal growth plate (Wang et al., 2010).
IGF-I derived from either the liver or bone can regulate longitudinal bone growth and
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contribute to proper growth plate development via growth hormone (GH) and thyroid
hormones (Ohlsson et al., 2009). Mice with reduced IGF-1 levels in the liver and serum,
including mice lacking ATRX in the developing forebrain, show defects in skeletal
growth and development, with reductions in trabecular number and mineral density
(Mohan et al., 2012; Watson et al., 2013). Similarly, development and remodeling of
bone and cartilage can also be affected by levels of thyroid hormone (Wojcicka et al.,
2012). Mutation of the thyroid receptor in mice causes delayed ossification during
development and increased mineralization later in life (Bassett et al., 2007; O’Shea et al.,
2005). Other models with defects in thyroid signaling leading to hypothyroidism have
growth retardation and defects in endochondral ossification (Bassett et al., 2008; Gauthier
et al., 2001). The thyroid also influences expression of calcitonin, which affects calcium
homeostasis and bone mineral density during growth and aging (Huebner et al., 2006).
Therefore, while endochondral bone formation is a highly regulated process in its own
right, overall body size and maturation of bone is controlled centrally by both the brain
and thyroid. Bone development is controlled both directly and indirectly, and any
pathologies must be considered to have both direct and indirect causes.

1.5

Osteoarthritis

Osteoarthritis (OA) is a common form of arthritis, frequently affecting the hips, knees,
and other freely moving or weight bearing joints (Felson et al., 2000; Radin et al., 1991).
It is a complex degenerative joint disease with a growing number of identified
biomechanical and systemic causes, and no known cure (Aigner et al., 2007; Aspden,
2008; Aspden, 2011; Felson et al., 2000; Goldring et al., 2009; Wang et al., 2011).
Primary OA currently affects 12% of adults aged 25–74 in the United States, with
similar incidences in the Canadian population (Lawrence et al., 2008; O'Donnell et al.,
2011). This incidence is only expected to increase with the aging population (Kopec et
al., 2008; Lawrence et al., 2008; Van Manen et al., 2012).
Onset and progression of osteoarthritis are dependent on the status of cartilage matrix
loss in the joint, and associated with disease phenotypes of stiffness, pain, and changes to
the underlying bone of the joint (Altman et al., 1986). Although osteoarthritis is
frequently associated with increased age, it can also originate from mechanical factors
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such as injury or obesity and systemic factors such as genetics or diet (Felson et al., 2000;
Ryder et al., 2008). These disease origins can be described in two groups; as primary
(idiopathic with no known origin) or secondary (post-traumatic) (Altman et al., 1986).
There is emerging evidence of important roles for chromatin remodeling in disease and
maintenance of articular cartilage, in addition to an already important role in
development and normal growth. Recent studies have identified important genetic
associations with osteoarthritis, including variants of DOT1L, an evolutionarily
conserved histone methyltransferase and SIRT1, a histone deacetylase (Castaño
Betancourt et al., 2012; Dvir-Ginzberg et al., 2013; Fujita et al., 2011; Gagarina et al.,
2010).
Chondrocytes embedded within the articular cartilage of the joint produce an
extracellular matrix (ECM) of collagens, proteoglycans, and other important
macromolecules to maintain cartilage integrity (Buckwalter et al., 2005). When
degeneration of the cartilage matrix exceeds the capacity of the chondrocytes to repair the
cartilage matrix, there is anabolism/catabolism imbalance, cartilage degeneration and
dysfunction associated with osteoarthritis. (Buckwalter et al., 2005; Goldring et al.,
2009).
Regulation of chondrocyte gene expression can therefore control the balance between
cartilage anabolism and catabolism, and ultimately cartilage homeostasis and
degeneration. For example, MMP13 (matrix metalloproteinase 13) is a collagenase upregulated in cases of osteoarthritis (Mort et al., 2001). It plays a catabolic role in the
progression of cartilage degeneration and cleaves collagens, gelatin, and aggrecan
(Fosang et al., 1996; Wang et al., 2011). In arthritic joints, MMP13 is upregulated,
resulting in the accelerated loss of the collagen matrix and ultimately the erosion of the
articular surface (Glasson et al., 2010). Mmp13 over expression in mice results in
spontaneous degeneration of the articular cartilage by accelerating type II collagen and
aggrecan degradation (Neuhold et al., 2001). Conversely, loss-of-function studies have
shown that MMP13 loss slows the progression of osteoarthritis after meniscal injury to
the knees (Little et al., 2009).
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Aggrecan is another extracellular matrix protein responsible for the compressive
resistance properties of cartilage. It is a proteoglycan with many charged, highly sulfated
sugars able to hold and release large quantities of water. Degradation of aggrecan into
fragments by specific MMPs and aggrecanase (ADAMTS) cleavage is common in
normal aging but accelerated in diseases such as OA (Pollard et al., 2008). Examining the
quantity

of

aggrecan

fragments

in

synovial

fluid

and

serum,

and

by

immunohistochemistry, is an effective method of detecting cartilage breakdown and thus
the progression of OA (Solursh et al., 1975). Similar to aggrecan, collagen 2 is an
extracellular matrix protein responsible for the compressive resistance and tensile
strength of cartilage. Collagen 2 is cleaved by a number of MMPs including MMP13.

1.6

Thesis Overview

This thesis presents the characterization of skeletal defects in mice with conditional
deletion of ATRX in cartilage, forelimb, and osteoblasts. Examining the phenotypes
associated with specific ATRX loss allows us to determine a molecular role for ATRX in
skeletal development and suggest possible treatments for ATR-X syndrome.

1.6.1

Rationale and Hypothesis

Many developmental disorders have associated skeletal phenotypes. Given the
importance of epigenetic regulation in the proper formation of the skeleton, it can be
predicted that these disorders may be indicative of a common pathway or a centralized
role of epigenetic regulation in the development of the skeleton. I hypothesized that the
specific skeletal defects observed in ATR-X syndrome are due to a direct role of ATRX
in the development of the skeleton. Additionally, loss of ATRX in skeletal tissues may
confer a susceptibility to skeletal pathologies later in life, including osteoarthritis.

1.6.2

Study One - Loss of Atrx in the Developing Chondrocyte

Chondrocytes determine skeletal element size, so I hypothesized that dwarfism and other
skeletal defects may be due to a role of ARTX in cartilage. I tested this hypothesis by
examining the outcome of cartilage-specific deletion of Atrx in mice. Using the Cre-loxP
system, I generated conditionally ATRX-deficient mice and characterized their skeletons
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during development and early life. My findings demonstrate that loss of ATRX,
specifically in chondrocytes, induces only minor skeletal defects, and does not affect
growth plate morphology or overall bone growth (Solomon et al., 2009).

1.6.3

Study Two - Atrx in the Developing Limb

Given the high frequency of skeletal abnormalities reported in ATR-X syndrome patients,
especially in hands and feet, I hypothesized ATRX has a direct role in the developing
limb. Given the results of Study 1, which showed no function of ATRX in the developing
cartilage, I deleted ATRX earlier in development during establishment of the limb. I
found that conditional deletion of Atrx in limb bud mesenchyme causes a specific and
significant shortening of the distal phalanges, which is similar to brachydactyly type A1
and brachydactyly type B in humans. I associated this phenotype with increased DNA
damage and cell death in the developing limb bud (Solomon et al., 2013, in revision).

1.6.4

Study Three - Loss of Atrx Does Not Confer Susceptibility to
Osteoarthritis

While there have been various developmental studies on ATRX, none have examined the
role of ATRX in cartilage maintenance and aging. As ATRX is expressed in
chondrocytes, it could be a potential epigenetic regulator of specific genes involved in
healthy cartilage maintenance. Mice lacking ATRX in the forebrain and pituitary have
premature aging phenotypes, linking ATRX to aging and potentially aging-associated
diseases (Watson et al., 2013). This study examined the role of ATRX in three models of
skeletal development and assessed the onset and progression of osteoarthritis using
Osteoarthritis Research Society International (OARSI) histopathology guidelines and
molecular markers of osteoarthritis. I found that mice lacking ATRX in cartilage, bone,
or forelimb mesenchyme did not demonstrate increased susceptibility to osteoarthritis in
adulthood. I also characterised the function of ATRX-deficient osteoblasts and found that
loss of ATRX does not affect the ability of osteoblasts to mineralise in vitro or in vivo.
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Chapter 2

2

Loss of Atrx in Chondrocytes has Minimal Effects on
Skeletal Development

Mutations in the human ATRX gene are known to cause developmental defects,
including skeletal deformities and dwarfism. ATRX encodes a chromatin remodeling
protein, however the role of ATRX in skeletal development is currently unknown. We
induced conditional Atrx deletion in mouse cartilage using the Cre-loxP system, with Cre
expression driven by the collagen II (Col2a1) promoter. Growth rate, body size and
weight, and long bone length did not differ in Atrx (Col2) cKO mice compared to control
littermates. Histological analyses of the growth plate did not reveal any differences
between control and mutant mice. Expression patterns of Sox9, a transcription factor
required for cartilage morphogenesis, and p57, a marker of cell cycle arrest and
hypertrophic chondrocyte differentiation, was unaffected. However, loss of ATRX in
cartilage led to a delay in the ossification of the hips in some mice. We also observed
hindlimb polydactily in one out of 61 mutants. In this chapter I demonstrate that ATRX
is not directly required for development or growth of cartilage in the mouse, suggesting
that the short stature in ATR-X patients is caused by defects in cartilage-extrinsic
mechanisms.
This chapter was previously published as (Solomon et al., 2009). Permissions for
reproduction are found in Appendix 1.

2.1 Introduction
ATR-X syndrome (Alpha-Thalassemia/Mental Retardation, X-linked) is a human
disorder caused by mutations in the ATRX gene (Gibbons et al., 1995a; Gibbons et al.,
1995b). Clinical manifestations include severe psychomotor and mental retardation,
characteristic facial features, urogenital abnormalities, skeletal deformities and αthalassemia (Gibbons et al., 1995a). Over 200 male ATR-X syndrome cases have been
reported (Gibbons et al., 2008), and female carriers are unaffected due to the skewed
pattern of X-inactivation (Gibbons et al., 2000). ATR-X syndrome patients display a
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wide range of skeletal abnormalities, and 66% of patients show dwarfism (Gibbons et al.,
2000). About half of ATR-X patients have spinal deformities such as kyphosis or
scoliosis (Gibbons et al., 1995a). Delayed bone age is characteristic of most cases studied
by thorough radiological investigation (Gibbons et al., 1995a). For some patients, these
skeletal abnormalities are apparent at birth, for others they manifest later in life, during
the pubertal growth spurt (Gibbons et al., 2000). Other skeletal deformities commonly
seen in ATR-X patients include clinodactyly, brachydactyly, tapering of the fingers,
overlapping digits, and 40% of patients have foot deformities (Gibbons et al., 1995a). A
single case of bifid thumb has been reported (Gibbons et al., 2000). Despite a broad
characterization of the variety of physical and mental phenotypes, very few
genotype/phenotype correlations have been established, and none are associated with the
severity of skeletal deformities (Badens et al., 2006). The molecular and genetic basis of
these phenotypes are therefore unknown and it is unclear if these defects are due to a
direct role of ATRX in the skeleton. Global knockout of Atrx using a ubiquitous GATACre system leads to placental defects and embryonic lethality (Garrick et al., 2006).
Conditional ablation of Atrx in the forebrain causes p53-dependent apoptotic cell death
during embryogenesis, resulting in a smaller brain at birth (Bérubé et al., 2005; Seah et
al., 2008a), while Atrx deficiency in the retina induces specific loss of interneurons
(Medina et al., 2009).
The ATRX protein contains a domain displaying high homology to SNF2 (Sucrose NonFermenting 2) proteins, suggesting a role as a chromatin remodeling protein (Picketts et
al., 1996). The SNF family of proteins is involved in transcriptional regulation,
maintenance of chromosome stability during mitosis and processing of DNA damage
(Eisen et al., 1995). ATR-X patient mutations are generally hypomorphic and do not
cause chromosomal instability (Gibbons et al., 2000). However, depletion of ATRX in
mammalian cells leads to defects in chromosome cohesion and mitotic progression
(Ritchie et al., 2008). In addition to its role during mitosis, ATRX appears to be involved
in the regulation of gene expression (Seah et al., 2008b).
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The development of long bones occurs through endochondral ossification, a highly
regulated multi-step process initiated when pluripotent mesenchymal cells aggregate to
form the beginning of a cartilage model (DeLise et al., 2000). Under the control of
several transcription factors, such as Sox9, Sox5, and Sox6 (Yamaguchi et al., 2000)
(Akiyama et al., 2002), mesenchymal cells differentiate into chondroblasts, which
produce large quantities of type II collagen (ColII) (Hoffman et al., 2003). Chondroblasts
mature to form chondrocytes, which undergo rapid proliferation along the longitudinal
axis of the future bone, forming the cartilage growth plate (Kronenberg, 2003). The
differentiated chondrocytes in the center of the cartilage model undergo hypertrophy,
increasing in cell size and secreting type X collagen (ColX) (Kronenberg, 2003). The
hypertrophic chondrocytes encased in calcified ECM secrete vascular endothelial growth
factor (VEGF), which recruits blood vessels bringing osteoblasts and osteoclasts to form
the primary ossification center; and eventually undergo apoptosis (Bobick et al., 2008).
Chondrocytes on either end of this primary ossification center continue to proliferate,
enter hypertrophy and undergo apoptosis, thus allowing the bone to grow longitudinally.
Finally, woven bone is laid down in the area of apoptotic chondrocytes and is remodeled
by osteoblasts and osteoclasts to form lamellar bone (Ducy et al., 2000).
To examine whether skeletal defects in ATR-X patients could be due to a requirement for
ATRX in cartilage development, we examined the outcome of cartilage-specific
inactivation of ATRX in mice, using the Cre-loxP system. Our findings demonstrate that
loss of ATRX specifically in chondrocytes induces minor skeletal defects, but does not
affect growth plate morphology and bone growth.

2.2
2.2.1

Materials and Methods
Histology and Immunohistochemistry

Histology and immunohistochemistry procedures were performed as described (Wang et
al., 2007) with minor modifications. Sections were incubated in 3% H2O2 for 15 min at
room temperature, followed by boiling for 2 min and incubation for 20 min at 97°C in 10
mM sodium citrate (pH 6.0). Paraffin sections were incubated with 5% goat serum for 30
min, and subsequently with primary antibodies (ATRX D-19) (Santa Cruz) at a dilution
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of 1:50 overnight at 4°C. Secondary goat anti-Rabbit HRP conjugated antibody (Santa
Cruz) at 1:200 dilution was used to recognize the primary antibodies. After washing, the
horseradish peroxidase (HRP) conjugated polymer complex was visualized by incubation
for 2 to 10 min with 3,3"-diaminobenzidine (DAB) substrate-chromogen (DAKO).
Sections were counterstained with methyl green, washed, and mounted.
All images were taken at room temperature with a Retiga EX camera (Leeds Precision
Instruments, Inc.) connected to a DMRA2 microscope (Leica). Image analysis was
performed using Openlab 4.0.4 software (Improvision).
Growth plate morphology was analyzed by Safranin-O stain on P0.5 and P21 long bone
sections. Sections were dewaxed, stained in haematoxylin followed by staining in fast
green and safranin-O. Proportions of resting, proliferating and hypertrophic cells were
determined using Openlab 4.0.4 software (Improvision) from at least three different mice.

2.2.2

Immunofluorescence of Cultured Primary Chondrocytes

Primary chondrocytes were prepared from long bones of E15.5 mouse embryos (James et
al., 2007). Briefly, long bones (tibia, femur, humerus) were dissected, rinsed in PBS and
incubated at 37°C for 20 min in trypsin-EDTA followed by digestion with 2 mg/ml
collagenase P at 37°C for 2 h in Dulbecco's Modified Eagles Medium (DMEM) with
10% FBS. The cell suspension was filtered through a 70 µm cell strainer (Falcon),
washed, counted and plated. For ATRX immunofluorescence, cells were grown on glass
coverslips and fixed for 15 min in 4% paraformaldehyde, then blocked with 5% goat
serum for 30 min at room temperature. Cells were then incubated with ATRX antibody at
a 1:300 dilution (H-300, Santa Cruz) and mouse anti-alpha tubulin at a 1:10,000 dilution
(Sigma) followed by FITC-conjugated anti-rabbit and Alexa 594-conjugated anti-mouse
secondary antibodies at 1:200 (Invitrogen). Slides were mounted in media containing
DAPI (Vectashield) and images were acquired on a Leica DMI 6000b automated inverted
microscope.

2.2.3

Mouse Breeding and Genotyping

Ethics Statement: All procedures involving animals were approved by the University of
Western Ontario Animal Care and Use Committee, Protocol 2007-045.
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Mice were exposed to a 12-hour light–dark cycle and fed tap water and regular chow ad
libitum. Mice conditionally deficient in ATRX were generated by crossing of AtrxLoxP
females (129sv background) (Garrick et al., 2006) with heterozygous Col2a1-Cre knockin male mice (Terpstra et al., 2003). The resultant conditionally Atrx-deficient offspring
from this cross are referred to as Atrx (Col2) cKO mice in this text. For developmental
studies, midday of the day of vaginal plug discovery was considered E0.5. At scheduled
times pregnant females were sacrificed by CO2.
PCR genotyping was performed from ear biopsy DNA for the presence of the Cre
transgene as previously described (Terpstra et al., 2003). Genotyping of embryonic and
newborn mice was performed using PCR of DNA isolated from skin biopsies. PCR
amplification was performed to detect the Atrx floxed alleles as previously described
(Seah et al., 2008a), the Cre transgene (Terpstra et al., 2003), as well as the sex
determining region Y (Sry) gene to identify male mice. A 1.5 kb fragment of neo gene
within the floxed allele of Atrx was identified with one set of primers (5'GATCGGCCATTGAACAAGAT-3' and 5'-ATA GGT CGG CGG TTC AT-3') whereas
the other set (5'-CCC GAG TAT CTG GAA GAC AG-3' and 5'-ATA GGT CGG CGG
TTC AT-3') amplified a 600 bp fragment of wild type. Primers (5’-CCT GGA AAA TGC
TTC TGT CC-3’) and (5’-CAG GGT GTT ATA AAC AAT CCC-3’) amplified a 300 bp
fragment of the cre gene, whereas the other set (5’-GCA GGT GGA AAA GCC TTA
CA-3’) and (5’-AAG CTT TGC TGG TTT TG GA -3’) amplified a 250 bp fragment of
Sry. PCR conditions were as follows: 95°C for 3 min (95°C for 30 s, 55°C for 45s, and
72°C for 1 min) x 36, 72°C for 10 min for Cre and Sry, 95°C for 3 min (95°C for 30 s,
55°C for 1 min, and 72°C for 5 min) x 36, 72°C for 10 min for Atrx.

2.2.4

Skeletal Stains and Measurements

Live mice were weighed at P0, P7 and P21. Whole body length was measured using a
ruler after sacrifice. For Alizarin Red/Alcian Blue staining, mouse carcasses were
skinned and eviscerated, then fixed overnight in 95% ethanol followed by overnight
fixation in acetone. Whole skeletons were placed in staining solution for 7-10 days
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(0.05% Alizarin Red, 0.015% Alcian Blue, 5% acetic acid in 70% ethanol) (Wang et al.,
2007). Skeletons were then cleared in 2% KOH. Images of stained bones were obtained
with an Olympus SP-57OUZ. Limb bones and skulls from four different littermate pairs
were measured using a dissecting microscope with a ruler.

2.2.5

RT-PCR

Five micrograms of total RNA obtained from Atrx (Col2) cKO and littermate control
chondrocytes and control brains was reverse-transcribed using Omniscript RT kit
(Qiagen) and used for PCR amplification with the following Atrx-specific primers: 17F
(5’ –AGA ACC GTT AGT GCA GGT TCA-3’) for exon 17 and 20a (5’-ACC ACC ATC
TTC TTG CCA TC -3’) for exon 20. Conditions for amplification were as follows: 95°C
for 3 min (95°C for 30 s, 56°C for 30s, and 72°C for 1 min) x 32, 72°C for 10 min.

2.2.6

Western Blot Analysis

Primary rib cartilage was isolated from newborn mice. Ribs were dissociated using
collagenase P and strained through a 70 µm nylon filter to remove ossified tissue,
followed by 3 days in culture over 1.5% agarose in PBS to specifically select for
chondrocytes (Beier et al., 1999). All tissues were lysed with MITO buffer (20mM
HEPES pH 7.5, 1 mM EDTA pH 8.0, 10 mM KCl, 1.5 mM MgCl2 and 1 protease
inhibitor cocktail tablet [Complete mini, EDTA-free; Roche]), followed by treatment and
lysis of nuclei with nuclear buffers without and with salt, respectively (20mM HEPES pH
7.9, 450 mM NaCl (omitted for no salt) 1.5 mM MgCl2, 0.2 mM EDTA pH 8.0 and 1
protease inhibitor cocktail tablet). Nuclear buffer without salt was used for swelling
nuclei, nuclear buffer with salt used for 25 min nuclear lysis on ice. Extracts were
quantified using the BCA protein assay (Sigma-Aldrich). Protein (5 µg) was resolved on
a 6 % SDS-PAGE and transferred onto nitrocellulose membranes (Bio-Rad
Laboratories). The membranes were probed with rabbit α-ATRX H300 (Santa Cruz
Biotechnology, Inc.) followed by the appropriate horseradish peroxidase–conjugated
secondary antibody (1:5,000; GE Healthcare). After washing, the membrane was
incubated in ECL before exposure using a ChemiImager 5500 (Alpha Innotech). The
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membrane was reprobed with mouse anti–beta-actin (1:10,000; Sigma-Aldrich) as a
loading control.

2.3
2.3.1

Results
Atrx is Expressed in Chondrocytes

Expression of Atrx in chondrocytes was assessed using in vitro and in vivo models.
Immunohistochemistry of embryonic, newborn (P0.5), and three week-old wild type mice
demonstrated that Atrx is expressed throughout the cartilage growth plate. Nuclear
staining of Atrx was apparent in all cartilage cells (Figure 2-1A). Primary chondrocytes
in monolayer culture were stained for Atrx by immunofluorescence. In interphase, we
observed a punctate staining pattern within the nucleus that corresponded to bodies
stained intensely with DAPI (Figure 2-1B, left panel). Alpha-tubulin (red) was used to
visualize the location of the cytoplasm and to identify microtubules during cell division.
During metaphase, ATRX was present exclusively at the edges of the aligned
chromosomes, similar to the localization at pericentromeric heterochromatin reported in
other cell types (Figure 2-1B, right panel) (Bérubé et al., 2000; Ritchie et al., 2008).
Western blots of primary cultured chondrocytes suggest that full-length Atrx was
expressed in cartilage (Figure 2-2B).

2.3.2

Loss of Atrx in Mouse Chondrocytes does Not Affect Viability
or Growth

We utilized the Cre-LoxP system to generate mice with cartilage-specific inactivation of
the Atrx gene. Female mice previously engineered with loxP sites flanking exon 18 of
Atrx (Bérubé et al., 2005) were mated with male mice expressing Cre recombinase under
the control of the mouse collagen II (Col2a1) promoter (Terpstra et al., 2003). Reverse
transcriptase PCR (RT-PCR) analysis of Atrx transcripts in cultured primary
chondrocytes confirmed a strong reduction in wild type Atrx mRNA and the presence of
low levels of a shorter transcript resulting from the recombination event in mutant
cartilage (Figure 2-2A).
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Figure 2-1 Expression and localization of ATRX in growth plate chondrocytes.
(A) Immunostaining of Atrx in humerus growth plates of P0.5 and P21 mice. Atrx is seen
in the nuclei of resting, proliferating and early hypertrophic cells in the growth plates
(arrows). Scale bar: 100 µm. Regions of the growth plate are identified as resting (red
arrow), proliferating (yellow), hypertrophic (green) and mineralized (blue). (B)
Immunofluorescence detection of Atrx in primary mouse chondrocytes isolated from
E15.5 long bones. Merged image of Atrx (green), DAPI (blue) and alpha-tubulin (red)
reveals a punctate Atrx staining pattern restricted to the nucleus during interphase (left
panel) and specific localization to condensed chromatin during mitosis (right panel).
Scale bar: 10 µm
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Figure 2-2 Levels of ATRX are decreased in the cartilage of Atrx(Col2) cKO mice.
(A) PCR analysis of cDNA from RNA isolated from newborn rib cartilage (Cr) or brain
(Br) from Atrx(Col2) cKO males (KO) and control littermates (Ctrl). Amplification was
performed with primers flanking the loxP sites, in exons 17 and 20. The expected
amplicon of 394bp was obtained in control and an additional amplicon of 254 bp was
obtained in cKO cartilage caused by the recombination event. The levels of the
recombined product are low, as described previously (Bérubé et al., 2005; Garrick et al.,
2006), suggesting that this product is unstable . (B) Immunoblotting for Atrx from
proteins isolated from newborn control and KO rib chondrocytes, calvariae and brain
tissue. Atrx expression is greatly reduced in KO chondrocytes, but unaffected in calvariae
and brain of cKO animals. Beta-actin was used as a loading control. (C)
Immunofluorescence detection of Atrx in control and Atrx(Col2) cKO primary
chondrocytes isolated from newborn long bones shows the loss of Atrx protein in KO
chondrocytes. Scale bar: 10 µm. (D) Immunohistochemistry on growth plates from P0.5
and P21 mice. Atrx staining is reduced in cKO growth plates. Scale bar: 100 µm.

54

These results confirm previous reports that the mRNA species generated by the
recombination event is unstable (Bérubé et al., 2005; Garrick et al., 2006). Levels of
Atrx protein in chondrocytes from ribs of newborn mice were assessed by
immunoblotting. Atrx protein amounts were substantially decreased in Atrx(Col2) cKO
chondrocytes (Figure 2-2B). In contrast, ATRX protein levels in brain and bone
(calvariae) were unchanged in mutant mice, validating the tissue specific activity of the
Col2a1 Cre (Figure 2-2B).

Loss of ATRX protein was further confirmed by

immunofluorescence of cultured chondrocytes isolated from Atrx(Col2) cKO and control
littermate mice (Figure 2-2C) and by immunohistochemistry on sections of Atrx(Col2)
cKO and control growth plates (Figure 2-2D). These data showed that our breeding
scheme resulted in specific and efficient loss of ATRX protein in cartilage.
Atrx(Col2) cKO mice were obtained at expected Mendelian ratios, indicating that loss of
ATRX in cartilage does not result in embryonic or neonatal lethality (59 control males,
61 cKO males out of 29 litters). In addition, Atrx(Col2) cKO mice showed no significant
difference in growth when weighed from birth to weaning and again at one year of age
(Figure 2-3A), or in body length at three weeks of age compared to wild-type littermates
(Ctrl: 6.30 cm STD: 0.21, cKO: 6.17 cm STD: 0.38, p>0.05). Body length at 6 and 12
months was also unaffected (data not shown). Atrx(Col2) cKO males were capable of
mating and producing offspring when backcrossed to floxed females to produce secondgeneration tissue-specific knockout mice.
Skeletal preparations from newborn and weanling (21 day old) Atrx(Col2) cKO mice
showed no change in skeletal morphology, bone length or extent of ossification, as
determined by the ratio of Alizarin red to Alcian blue staining in the long bones (Figure
2-3B,C). Length of tibia, femur, radius, ulna, and humerus were measured, as well as the
length and width of the skulls. Average measurements obtained from four independent
littermate pairs revealed no significant changes in the length of long bone elements
between control and mutant mice (Figure 2-3D).
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2.3.3

Growth Plate Morphology is Not Affected by the Loss of Atrx

Histochemical staining was conducted on paraffin sections of the growth plates of
Atrx(Col2) cKO and control mice to examine proportions of resting, proliferative and
hypertrophic zones. No difference in growth plate architecture or chondrocyte

Figure 2-3 Effects of ATRX loss-of-function on growth and development of the
skeleton.
(A) Weight measurements from control and cKO mice. No differences were seen in the
growth of Atrx(Col2) cKO mice compared to control littermates, and weight gain was
normal at all stages of development. N>5 for all timepoints (B, C) Skeletal stains of
newborn and p21 control and cKO mice showing cartilage (blue) and bone (red)
proportions. Extent of limb ossification and skeletal proportions between control and
mutant pups were unaffected at birth and at three weeks (D) Long bone lengths and skull
proportions were measured from four control/cKO littermate pairs at P21, and found to
be unaffected by Atrx loss. N = 4, error bars = SD.
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morphology was detected between genotypes at P0.5 or P21 (Figure 2-4A). In agreement
with these data, no significant differences were seen in the length of any growth plate
zone in three independent litters (Figure 2-4B). The early chondrogenic marker Sox9 was
expressed in resting and proliferating chondrocytes of control and cKO sections,
demonstrating that loss of Atrx in growth plates had no effect on Sox9 expression (Figure
2-4C). To confirm that differentiation was unaffected in mutant chondrocytes, long bone
sections were stained for p57, a cyclin-dependent protein kinase inhibitor that is
expressed by prehypertrophic, postmitotic chondrocytes (Zhang et al., 1997). The pattern
of p57-positive cells in the mutant growth plates at P0.5 and P21 (Figure 2-4D) was not
different between control and mutant mice, suggesting that loss of ATRX in the cartilage
growth plate does not affect terminal differentiation of chondrocytes. In addition, the
expression of other cartilage markers such as ColX, ColII, or aggrecan was not altered at
P0.5 or at P21, indicating that chondrocyte differentiation was unaffected by loss of
ATRX expression in cartilage.

2.3.4

Conditional Loss of Atrx in the Mouse Skeleton Causes
Minor Ossification Defects

Although no overall changes in skeletal size or proportions were seen in the Atrx(Col2)
cKO mice, minor delays in development were seen in some mice. Half (2 of 4) of the
mutants examined by skeletal staining at day 21 displayed a delay in ossification of the
union between the pubis and the ischium (Figure 2-5A). In those mutant mice where
ossification was complete by day 21, the site of union was uneven with a spur-like bone
projection. Both phenotypes suggest a mild defect in the ossification of the hip in the
Atrx(Col2) cKO mice.
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Figure 2-4 ATRX-null growth plates are indistinguishable from controls.
(A) Growth plate sections from control and Atrx(Col2) cKO mice at P0.5 and P21 were
stained with safranin-O/Fast green, demonstrating unaltered growth plate architecture and
morphology in mutant mice. Scale bar: 100 µm. (B) No significant difference in the
length of the resting, proliferating or hypertrophic zones could be detected between
genotypes at birth or weaning (N=3 littermate pairs; two-tailed T-test). Error bars depict
standard error of the mean (SEM). (C) Expression of Sox9, an early chondrocyte
differentiation marker expressed in resting and proliferating chondrocytes, is not altered
in the absence of Atrx at P0.5 or P21. Scale bar: 50 µm. (D) Immunohistochemistry for
the differentiation marker p57 reveals that Atrx loss has no effect on the proportion of
chondrocytes reaching terminal differentiation. Scale bar: 100 µm.
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Figure 2-5 Minor defects observed in Atrx(Col2) cKO mice.
(A) Pelvis phenotype of P21 control and Atrx(Col2) cKO mice. Arrows indicate the site
of delayed ossification in mutant mice. (B) Hind limb of mutant mouse with one
additional digit, before and after skeletal preparation to stain for cartilage (blue) and bone
(red). The additional digit is indicated by an arrow.
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A second phenotype observed in one of the 61 Atrx(Col2) cKO mice was an extra digit in
a hind foot (Figure 2-5B). This digit resembled an additional toe, similar to the fourth
toe, rather than a bifurcation of the fifth toe. The toe appeared normal, and in skeletal
preparations showed no gross differences from other digits.

2.4

Discussion

In this study, we show that loss of the Atrx protein specifically in cartilage of mice does
not cause a major defect in skeletal growth or development. Although ATRX loss in the
cartilage of mice was confirmed by immunohistochemistry, immunofluorescence and
western blot analyses, we show that long bones from Atrx(Col2) cKO mice do not differ
from controls in length or growth-plate morphology, and that these mice achieve the
same adult length and weight as control littermates. Furthermore, mutant mice are viable
and breed normally, with no defects seen in second-generation knockouts. Whole skeletal
stains for ossified bone and cartilage were used to characterize the entire skeleton of
Atrx(Col2) cKO mice. Qualitative and quantitative study of the control and Atrx(Col2)
cKO skeletons showed no overall changes in cartilage proportions and lengths of
individual elements.
The minor defects observed in our mouse model suggest a mild effect from ATRX
deficiency that may manifest only occasionally. This is not unexpected, as the limb and
digit phenotypes observed in ATR-X syndrome patients are also highly variable. In a
study of sixty-five unrelated patients, one case of bifid thumb was observed (Badens et
al., 2006). The varied hand and foot deformities in some ATR-X patients suggest that the
effect on limb development may differ between individuals, even those with identical
mutations (Badens et al., 2006). Thorough radiologic investigations of ATR-X patients
have shown that the most common phenotypic abnormalities were delayed bone age and
coxa valga (Gibbons, 2006). The delay in hip ossification seen in our mice may be due to
a similar delay in bone age.
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Previous studies have shown that loss of ATRX in other tissues in the mouse causes
severe and fatal defects (Bérubé et al., 2005; Garrick et al., 2006; Medina et al., 2009).
Loss of ATRX in the mouse forebrain has been shown to result in widespread
hypocellularity in the hippocampus and neocortex, as well as an overall reduction in
forebrain size. These mice exhibit reduced weight and perinatal lethality, demonstrating
the importance of ATRX in the brain (Bérubé et al., 2005). Similarly, loss of ATRX in
the 16-cell morula stage has revealed a specific and essential role for ATRX in the
formation of the extraembryonic trophoblast in mice. Mutant mice showed a dramatic
reduction in mitotic cells and early embryonic death at E9.5 (Garrick et al., 2006). A third
model examining the role of ATRX in the developing retina showed that ATRX loss-offunction leads to loss of interneurons, specifically, amacrine and horizontal cells. These
mice demonstrated a defect in interneuron differentiation and survival, which is
associated with functional deficits that may be similar to the subset of ATR-X patients
with visual anomalies (Medina et al., 2009).
This is the first study examining the specific loss of ATRX in the skeletal system, and
surprisingly we observed only minor abnormalities. Since these effects are much less
severe than in all other cell types examined, despite marked expression of ATRX in wild
type chondrocytes, our data suggest cell type-specific requirement for ATRX function in
cell survival and differentiation.
One assumption in our model is that destabilization and subsequent breakdown of the
Atrx mRNA is an accurate model of the hypomorphic gene expression seen in ATRX
patients. While our model deletes only the long isoform of ATRX and retains the short
isoform (ATRXt), it is unlikely that ATRXt has equivalent functions to the full length
protein, as it lacks the functional SWI/SNF domain (Garrick et al., 2004). In addition, the
same floxed Atrx mouse line has been used by us and others to successfully conduct loss
of function studies in other organs, such as the brain (Bérubé et al., 2005; Seah et al.,
2008a) or eye (Medina et al., 2009). Since loss of ATRX does not affect cartilage
development in mice, it seems likely that the skeletal defects in ATR-X patients are not
due to direct effects of the mutant proteins in chondrocytes.
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We have used the cartilage-specific collagen II promoter driving cre to inactivate the Atrx
gene. However, there remains a possibility that some of the limb phenotypes seen in
ATR-X patients (e.g. patterning defects affecting the digits) are due to an earlier effect,
such as a function in formation or outgrowth of the limb bud or in formation of the initial
mesenchymal cell template. Since loss of ATRX occurs later in development in our
model, we cannot rule out such an earlier function for the protein. Use of an early limb
bud-specific promoter, such as the Prx1 limb enhancer (Logan et al., 2002), to direct Atrx
inactivation could answer this outstanding question. Additionally, a later deficiency may
also contribute to the observed patient skeletal abnormalities. For example, defects in
osteoblasts could contribute to delayed bone age seen in patients or reduced overall
growth. Atrx deletion specifically in osteoblasts could be induced by using the a1(I)collagen promoter to drive cre expression (Dacquin et al., 2002). These experiments are
discussed within Chapter 4 of this thesis.
An alternative explanation for the surprising lack of skeletal defects in our mice is that
the skeletal defects observed in patients might be secondary to abnormalities in other
organs, such as neuroendocrine defects stemming from ATRX dysfunction in the nervous
system (Ballock et al., 2003). There is much new evidence demonstrating that bone
growth can be regulated centrally via cytokines, hormones and transcription factors,
including the hormone leptin (Takeda, 2005). Experiments using leptin directly on bone
cells have shown no effect on bone remodeling, however intracerebroventricular leptin
infusion into leptin-deficient mice leads to an effect on bone mass via the nervous system
(Takeda, 2005). Similarly, hematopoietic systems within the bone marrow have been
shown to be influenced by the neurohormone melanin and catecholamines (Maestroni,
2000). Both factors also have hematopoietic roles, and are present in substantial amounts
in the bone marrow, supporting the idea that neural and neuroendocrine factors have a
direct effect on the bone microenvironment. Together, these studies suggest that cell
defects in the hypothalamus (in the case of leptin) or the pineal gland (in the case of
melatonin) may have a central influence on the development and homeostasis of the
skeleton.
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Importantly, it appears likely that the large variety of skeletal and growth abnormalities in
ATRX patients does not have one common cellular origin; instead it appears that some
defects (e.g. digit malformations) could be due to alterations in the early patterning of the
limb, others (such as delayed bone age) could be caused by defects in osteoblasts (or
possibly osteoclasts) and a third group (such as growth retardation) could be caused by
abnormal neuroendocrine signaling.

These possibilities will require examination as

alternative mechanisms for the pathogenesis of ATR-X syndrome.
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Chapter 3

3

Targeted Loss of the ATR-X Syndrome Protein in the
Limb Mesenchyme of Mice Causes Brachydactyly

ATR-X syndrome is a rare genetic disorder caused by mutations in the ATRX gene.
Affected individuals are cognitively impaired and display a variety of developmental
abnormalities, including skeletal deformities.

To investigate the function of ATRX

during skeletal development, we selectively deleted the gene in the developing forelimb
mesenchyme of mice. The absence of ATRX in the limb mesenchyme resulted in shorter
digits, or brachydactyly, a defect also observed in a subset of ATR-X patients. This
phenotype persisted until adulthood, causing reduced grip strength and altered gait in
mutant mice. Examination of the embryonic ATRX-null forelimbs revealed a significant
increase in apoptotic cell death, which could explain the reduced digit length.

In

addition, staining for the DNA-damage markers γ-H2AX and 53BP1 demonstrated a
significant increase in the number of cells with DNA damage in the embryonic ATRXnull forepaw. Strikingly, only one large bright DNA damage event was observed per
nucleus in proliferating cells. These large γ-H2AX foci were located in close proximity
to the nuclear lamina and remained largely unresolved after cell differentiation. In
addition, ATRX-depleted forelimb mesenchymal cells did not exhibit hypersensitivity to
DNA fork-stalling compounds, suggesting that the nature as well as the response to DNA
damage incurred by loss of ATRX in the developing limb fundamentally differs from
other tissues. Our data suggest that DNA damage-induced apoptosis is a novel cellular
mechanism underlying brachydactyly that might be relevant to additional skeletal
syndromes.

3.1

Introduction

Alpha-Thalassemia Mental Retardation Syndrome, X-linked (ATR-X [MIM 301040]) is
a rare genetic disorder caused by mutations to the ATRX gene (Gibbons et al., 1995b).
Manifestations of the disease include intellectual disabilities, severe developmental delay,
facial dimorphisms, urogenital abnormalities, and skeletal deformities (Gibbons et al.,
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1995a; Gibbons et al., 2000a). The latter include brachydactyly, clinodactyly, tapering of
the fingers, overlapping digits, and foot deformities.

Approximately two-thirds of

patients have short stature (Gibbons et al., 1995a; Gibbons et al., 2000a). This X-linked
syndrome predominantly affects males whereas carrier females are mostly asymptomatic,
presumably due to skewed X-inactivation (Gibbons et al., 1995a; Wada et al., 2005).
Many ATR-X patients have α-thalassemia caused by impaired production of the α-globin
gene leading to unstable tetramers of β-globin chains, or HbH inclusions, in the blood
(Gibbons et al., 2000b; Gibbons et al., 1995b).
The ATRX protein contains two highly conserved domains where the majority of
disease-causing mutations are located.

A plant homeodomain-type (PHD-type) zinc

finger motif, also called the ADD domain, mediates binding to histone H3 trimethylated
at lysine 9 and unmethylated at lysine 4 (Dhayalan et al., 2011; Otani et al., 2009; Wong
et al., 2010). ATRX also contains a Sucrose Non Fermenting 2 (SNF2)-type DNAdependent ATPase domain in the C-terminal portion of the protein (Gibbons et al.,
1995a; Picketts et al., 1996). SNF2 proteins are a family of helicase-like proteins that can
hydrolyse adenosine triphosphate (ATP) to remodel chromatin or help repair DNA
damage (Eisen et al., 1995).
The ATRX protein interacts with the heterochromatin protein 1 alpha (HP1α) and the Fas
death domain-associated protein (DAXX), proteins located at heterochromatin and
promyelocytic leukemia (PML) nuclear bodies (Xue et al., 2003). The DAXX/ATRX
complex deposits the histone variant H3.3 at telomeres and at pericentromeric
heterochromatin and can modulate transcription from these highly repetitive genomic
regions (Drané et al., 2010; Lewis et al., 2010).
Emerging evidence indicates that ATRX is required to maintain genomic integrity.
Depletion of ATRX in human somatic cells by RNA interference caused mitotic defects
including chromosome cohesion, congression and segregation defects (Ritchie et al.,
2008). In the mouse, conditional inactivation of Atrx in forebrain, muscle and Sertoli cells
was reported to induce cell death (Bagheri-Fam et al., 2011; Bérubé et al., 2005; Garrick
et al., 2006; Huh et al., 2012).

Surprisingly, we showed that deletion of Atrx in
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chondrocytes did not result in increased cell death, demonstrating that the outcome of
ATRX deficiency differs across cell types (Solomon et al., 2009). In mouse embryonic
stem cells, ATRX depletion results in reduced histone H3.3 deposition at telomeres and
in telomere-dysfunction phenotypes (Wong et al., 2010). Our group and others have
shown that increased instability at telomeres associated with ATM activation occurs upon
ATRX inactivation (Huh et al., 2012; Watson et al., 2013). We demonstrated that
combined deletion of the p53 and Atrx genes in the developing nervous system abolishes
embryonic cell death, leading to an accumulation of neurons with DNA damage. Thus,
loss of ATRX causes DNA damage, which triggers p53-dependent apoptotic cell death
(Seah et al., 2008; Watson et al., 2013). ATRX-deficient cells are hypersensitive to forkstalling agents, but not to gamma irradiation, suggesting that loss of ATRX specifically
promotes DNA replication stress (Leung et al., 2013; Watson et al., 2013). This is
supported by the co-localization of DNA damage foci with the replication marker PCNA
in ATRX-null cells (Huh et al., 2012; Watson et al., 2013). Leung et al. demonstrated that
ATRX is recruited to sites of DNA damage with the MRN complex and promotes restart
of stalled forks (Leung et al., 2013). Finally, we were able to show that neuroprogenitors
lacking ATRX accumulate more DNA damage and display reduced survival upon
treatment with telomestatin, a G-quadruplex ligand, suggesting that replication stress
induced by ATRX deficiency is linked to G-quadruplex stability (Watson et al., 2013).
Given the high frequency of skeletal abnormalities reported in ATR-X syndrome patients,
especially in hands and feet, we hypothesized that ATRX may protect cells in the
developing limbs from endogenous DNA replication damage or that it might control
pathways required for proper development of the skeleton in the distal limbs. We find
that conditional deletion of Atrx in limb bud mesenchyme causes a specific and
significant shortening of the distal phalanges. Embryonic ATRX-null limb bud cells
display one large γ-H2AX/53BP1-positive focus adjacent to the nuclear membrane in
each nucleus that persists upon cell differentiation. While the majority of cells seem to
be able to differentiate despite unrepaired DNA damage, we detected an increase in
apoptotic cell death that might explain the reduced digit length in the Atrx(Prx1) cKO
mice. Our findings suggest that apoptosis in response to DNA damage is a novel
mechanism giving rise to brachydactyly.
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3.2
3.2.1

Materials and Methods
Mouse Husbandry, Genotyping and Tissue preparation

Mice were housed with a 12-hour light-dark cycle, and fed tap water and regular chow ad
libitum. Mice conditionally deficient for Atrx in the early limb bud mesenchyme were
generated using the 129SV AtrxloxP mice described previously(Bérubé et al., 2005;
Garrick et al., 2006).

AtrxloxP mice were mated to mice expressing transgenic Cre

recombinase under the control of the Prx1 promoter (Prrx1-cre)(Logan et al., 2002) to
generate AtrxloxP/Prx1Cre+ animals lacking ATRX in the developing forelimb. Tg(Prrx1cre)1Cjt mice were obtained from Jackson Laboratories. For embryonic time points, noon
of the day after mating was considered to be E0.5. Genotyping for Atrx, Cre, and Y
chromosome was determined by PCR as previously described (Bérubé et al., 2005; Seah
et al., 2008). Embryonic tissue collected for histology was fixed in PFA overnight at 4°C
overnight, then equilibrated in 30% sucrose and embedded in VWR clear frozen section
compound over liquid nitrogen. Forelimbs were sectioned at 5 µm and stored at -80°C.
All procedures involving animals were conducted in accordance with the regulations of
the Animals for Research Act of the Province of Ontario and approved by the University
of Western Ontario Animal Care and Use Committee, Protocol 2007-045.

3.2.2

Quantification of Skeletal Defects

Embryonic forepaws were isolated and dehydrated in 95% ethanol for 24 h, followed by
acetone for 24 h. Paws were then stained with 0.015% alcian blue, 0.05% alizarin red,
and 5% acetic acid in 70% ethanol as described(Wang et al., 2007). The stained paws
were cleared in glycerol/1% KOH (1:1) and stored in glycerol/ethanol (1:1). Adult
skeletons were cleaned and stained as described, then cleared in 2% KOH and stored in
glycerol/ethanol (1:1). Embryonic forepaws were cleared and imaged using a Nikon
SMZ1500 dissecting microscope with a Photometrics (Tucson, AZ) Coolsnap camera
using ImageMaster 5.0 software. Adult phalanges were microdissected and imaged as
described. Digit length was measured in ImageJ and analysed using Graphpad from at
least three independent litters at each age. Means were compared using a student's T-test.
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3.2.3

Microcomputed Tomography

Mice were euthanized at P21, forelimbs were dissected and fixed in paraformaldehyde
overnight followed by immobilisation in agarose. Whole forepaws were scanned on a GE
Locus scanner at 80 kV and 0.08 mA with a 0.013 mm3 voxel resolution with 900 slices
per scan. Scans were analysed using Microview 3D visualization and analysis software
(MicroView, Version 2.1.2, GE Healthcare Biosciences), as described (Ulici et al., 2009).
Whole forepaw isosurface images were generated by applying a threshold of 932 HU,
surface quality factor of 1.00 and a surface decimation factor of 30.

3.2.4

Western blot Analysis

Embryonic forelimbs were dissected in PBS into RIPA buffer and homogenised using a
fine-gauge needle. SDS-PAGE sample buffer (5 µl) was added to samples, followed by
boiling for 5 min. Samples were separated by gradient SDS-polyacrylamide gel
electrophoresis (Biorad) and transferred to nitrocellulose membranes (Amersham).
Membranes were blocked in 2% BSA and incubated with primary antibodies in
accordance with the instructions from the primary antibody supplier. Representative blots
from three independent experiments are shown.

3.2.5

Proliferation and Cell Death Assays

Proliferating cells were visualized using antibodies for Ki67. Frozen sections were
rehydrated and antigens retrieved using 0.1 M sodium citrate.

Sections were

permeabilized for one hour with blocking buffer containing 5% goat serum and 0.1%
tween-20 in phosphate-buffered saline, followed by overnight incubation with primary
antibodies mouse anti-gamma H2AX (Abcam) and either rabbit anti-53BP1 (Cell
signalling) or rabbit-antiKi67 (Abcam) at a concentration of 1:300 in blocking buffer.
Antibodies were detected using fluorescently conjugated secondary antibodies, FITC goat
anti-rabbit (Biosource) and Alexa-594 goat anti-mouse (Invitrogen) at dilutions of 1:200.
Slides were mounted in media containing DAPI (Vectashield) and confocal images were
acquired on an Olympus FluoView TV1000 coupled to the IX81 Motorized Inverted
System Microscope (IX2 Series). Damage was quantified by a blinded observer within a
fixed area of 10,000 µm2 for digit tips and 5,000 µm2 for digit rays. Counts were
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averaged from three independent litters at each time point. To assess apoptosis, 5 µm
sections from E13.5 and E15.5 mice were used for the TUNEL assay using the Roche In
Situ Cell Death Detection Kit, Fluorescein according to manufacturer's instructions.
Briefly, frozen sections were hydrated in PBS and treated with cold citrate for 2 min.
Slides were washed and incubated in the enzyme/label solution mix for 1h at 37oC, then
mounted with DAPI-containing mounting media (Vectashield). Sections were imaged on
a Leica DMRA2 automated inverted microscope. Signal was quantified from sections
using a fixed area over each digit by a blinded observer. Counts were averaged from at
least three independent litters.
Activated caspase 3 was visualised in sections using rabbit anti-cleaved caspase-3 (Cell
Signaling, 1:400 dilution). Cryosections were rehydrated in 1XPBS for 5 min and
subjected to antigen retrieval by heating 0.1M sodium citrate ph6 to 95 degrees. Sections
were permeabilized with 1X PBS/0.3% Triton X for 5 min and incubated with primary
antibody diluted in 1XPBS/0.3% Triton-X overnight at 4 degrees. Sections were washed
3X with 1X PBS/0.3% Triton X for 5 min each and incubated with goat anti-rabbit Alexa
488 (1:800 dilution) diluted in 1XPBS/0.3% Triton-X for 1h at RT. Sections were
washed 2X with 1X PBS/0.3% Triton X for 5 min each, incubated with 1µg/µl
DAPI/1XPBS for 5 min, and washed 3X with 1X PBS/0.3% Triton X for 5 min each.
Slides were then mounted using SlowFade Gold (Invitrogen) and imaged using an
inverted fluorescence microscope (Leica, DMI6000b).
Immunofluorescence assays were conducted for γ-H2AX and the nuclear envelope
marker Lamin-B as described previously (Kuo et al., 2008; Vidaković et al., 2005).
Nuclear lamina was detected using a goat anti-LaminB antibody (Abcam) at a
concentration of 1:300 while DNA double strand breaks were visualized with mouse antiγ-H2AX (Abcam) at a concentration of 1:200 in blocking buffer and detected with
Alexa-594 donkey anti-mouse (Invitrogen) and FITC donkey anti-goat (Invitrogen) at a
concentration of 1:200. Three-dimensional images of nuclei were collected on an
Olympus FluoView TV1000 coupled to the IX81 Motorized Inverted System Microscope
(IX2 Series) in image stacks captures at 0.25 µm Z-sections and deconvoluted in
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Volocity (PerkinElmer). Measurements were taken from the center of the γ-H2AX focus
to the closest nuclear periphery for 100 individual nuclei.

3.2.6

Hydroxyurea Treatment and Assessment of DNA Damage
and Survival

Primary forelimb mesenchyme was prepared using distal forelimb tissue dissected from
E13.5 embryos. Cells were dissociated with collagenase at 37oC for one hour and plated
in DMEM/F12 media supplemented with 10% FBS, 0.25% pen/strep and 0.25% lglutamate (Gibco). Forelimb mesenchyme cultures were treated with increasing doses of
HU (0.05 to 1 mM) for 24 hours, recovered for 24 or 48 hours, and cell viability
measured by MTT assay as described (Halawani et al., 2004). Briefly, media containing
HU was removed and replaced with fresh media for 24 or 48 h, followed by replacement
with media containing 0.5 mg/ml MTT for 4 h. Product was stabilized in DMSO and
quantified on a spectrophotometer at 595 nm.

3.2.7

Gait and Grip Strength Analyses

Behavioural assays were performed at the behavioural core facility at the Robarts
Research institute (London, ON). Control and mutant mice at P21 and one year of age
freely ambulated on an illuminated glass platform, and movements were recorded with a
high speed camera using the Noldus CatWalk system. After an initial training period, at
least three uninterrupted runs were collected from each animal. Each run was analysed
using Catwalk 7.1 software for classifying foot contacts. Run data for each animal were
averaged, and then averages calculated within each genotype. Means were analyzed for
statistical differences between genotypes using a student’s t -test. Mouse forelimb grip
strength was assessed using a digital force gauge as described previously (Meyer et al.,
1979). Briefly, the animal was grasped by the scruff of the neck in one hand, and the base
of the tail in the other. Measurements were recorded on the meter as the subject was
allowed to grip, and then was pulled away from, the grip bar. Total peak force was
determined from an average of five measurements taken from each animal, and the means
of each genotype were compared. Statistical analysis of the means was conducted using a
two-tailed student's t-test.
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3.3
3.3.1

Results
Generation of Mice Lacking Atrx Specifically in the Limb
Mesenchyme

We utilized the Cre-LoxP system to generate mice lacking the Atrx gene in early limb
bud mesenchyme. Homozygous floxed AtrxloxP female mice (Bérubé et al., 2005) were
mated with male Tg(Prx1-cre)1Cjt mice expressing Cre recombinase under the control of
the Prx1 promoter that drives recombination in early limb bud mesenchyme (Logan et al.,
2002). Since Atrx is located on the X chromosome, males resulting from this cross carry
one copy of the Atrx gene that contains the loxP sites. Cre-positive males are
conditionally ATRX-null and are referred to as Atrx(Prx1) cKO. All animals in this study
were from the first generation of this cross.
Reverse transcriptase PCR (RT-PCR) analysis of Atrx expression in embryonic day 16.5
forepaws shows a reduction in wild type Atrx mRNA and the presence of low levels of a
shorter transcript resulting from the recombination of exon 18 in mutant limb
mesenchyme. The amount of this truncated RNA was greatly reduced, confirming that
the RNA is unstable and is equivalent to a null mutation (Figure 3-1A), as we have
shown previously (Bérubé et al., 2005). ATRX protein was detected at high levels in the
control, but was absent in the cartilage and pre-cartilaginous condensations of the
Atrx(Prx1) cKO mice (Figure 3-1B,C). ATRX protein is retained in the nucleus of
epithelial cells of the limb, confirming that Cre activity is indeed limited to the limb
mesenchyme when expressed under the control of the Prx1 promoter. Mutant Atrx(Prx1)
cKO mice were born at normal Mendelian ratios (Figure 3-1D) and had a normal birth
weight (Figure 3-S1). They lived beyond the age of one year and were fertile.
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Figure 3-1 Atrx is deleted in the forelimbs of Atrx(Prx1) cKO mice
(A) RT-PCR analysis of RNA isolated from embryonic forelimbs of Atrxfl/yPrxcre+ males
Atrx(Prx1) cKO (KO) and control littermates (Ctrl). Amplification was performed with
primers flanking the loxP sites, in introns 17 and 20. Recombined RNA in Atrx(Prx1)
cKO is unstable and degraded. (B) Cryosections of E15.5 forelimb tissue were stained for
ATRX protein. Atrx(Prx1) cKO mice lack ATRX in the nucleus of all mesenchyme
tissues. Scale bar: 200 µm (representational high-resolution image: 50 µm) (C)
Immunoblot of proteins isolated from E15.5 forelimbs shows loss of ATRX protein in
Atrx(Prx1) cKO mice. (D) Atrx(Prx1) cKO mice are born at normal Mendelian ratios,
with no associated lethality.
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3.3.2

Mice lacking Atrx in the Forelimb Mesenchyme Develop
Brachydactyly

To evaluate the phenotypes of Atrx(Prx1) cKO mice, forelimbs were collected and
patterns of cartilage and mineralised bone were examined at various embryonic times by
alcian blue/alizarin red staining (respectively).

Embryonic forepaws showed no

difference between control and mutant mice at embryonic day 14.5 (Figure 3-2A).
However, at E15.5, we observed that the condensation of the anlage for phalange 2 was
reduced in size (Figure 3-2B).

A more severe delay was seen at E16.5. The paws in

controls had four cartilage condensations and establishment of phalange 3, while these
condensations were significantly shortened or absent in the Atrx mutant littermates
(Figure 3-2C). At this stage of embryonic development, the Atrx(Prx1) cKO embryos
displayed a significant shortening of total digit length, with smaller ossified elements in
the distal phalanges. This phenotype is consistent with brachydactyly in ATR-X
syndrome (Gibbons, 2006).
Whole skeletal preparations were obtained from newborn, weanling (P21), and adult
mice.

Distal phalanges in Atrx(Prx1) cKO mice displayed reduced or absent

mineralisation at birth and were significantly shorter than the phalanges of control
littermates (Figure 3-3A). This phenotype was evaluated at P21, and we found that the
shortening of the distal phalanges persisted even after complete mineralisation of the paw
(Figure 3-3B). Proximal phalanges (metacarpals and phalange 1) were not affected,
whereas the distal phalanges (phalanges 2 and 3) are significantly shorter in all digits.
Micro-computed tomography analysis of P21 forepaws was performed and showed that
the shape of the fingers and claws is altered. Fingers displayed abnormal flexation, while
mineralization and cortical thickness are not affected (Figure 3-3C). Adult Atrx(Prx1)
cKO mice still exhibit brachydactyly at one year of age (Figure 3-3D), indicating that the
early phenotypes do not simply represent a delay in development but rather a permanent
phenotype. The proximal bones of mutant forelimbs (humerus, radius, ulna) did not show
any abnormalities at any investigated age.
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Figure 3-2 Atrx(Prx1) cKO digit defects appear at embryonic day 15.5
(A) Phalange length measurements from embryonic day 14.5 Atrxfl/yPrxcre- (CTRL) and
Atrx(Prx1) cKO (cKO) mice. No differences are seen in the length of cartilaginous
condensations in the forelimb. (B) Phalange length measurements at embryonic day 15.5.
cKO mice exhibit shortening of terminal phalanges. (C) Phalange length measurements
from embryonic day 16.5. All distal phalanges are significantly shortened in mutant mice.
* = p < 0.05, N=3. Arrow indicates shortened phalange.
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Figure 3-3 Atrx(Prx1) cKO mice show brachydactyly
(A) Skeletal stains of control (Ctrl) and Atrx(Prx1) cKO (KO) newborn (P0.5) forelimbs.
Cartilage is stained in blue, mineralised tissue is stained in red. Proximal bones
(metacarpals and the first phalange) were not affected in the mutant, however distal
phalanges were significantly shortened and lacked mineralisation. * = p < 0.05, N=3 (B)
Skeletal stains of control (Ctrl) and Atrx(Prx1) cKO (KO) weanling (P21) forelimbs.
Significant shortening is observed in all phalanges, excluding the metacarpals * = p <
0.05, N=3. (C) MicroCT isosurfaces of P21 digits. Atrx(Prx1) cKO digits lack flexation
of the terminal phalanges, and have short, malformed claws. Cortical thickness was
unaffected. Scale bar: 1 mm (D) Skeletal stains of control (Ctrl) and Atrx(Prx1) cKO
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(KO) adult (1 year old) forelimbs. Mineralised tissue is stained in red. Significant
shortening is observed in all phalanges. N=3 for all time points, * = p < 0.05.
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3.3.3

Cell Death is Increased in the Atrx(Prx1) cKO Embryonic
Limb Bud Mesenchyme.

The observation that Atrx(Prx1) cKO mice have shorter digits suggests a reduction in cell
numbers during embryogenesis, which could be explained by reduced proliferation or
increased cell death.

Proliferation was assessed using Ki67 staining (a marker of

proliferation). Quantification of Ki67-positive cells in the distal portions of control and
Atrx(Prx1) cKO digits showed that cell proliferation is not different between genotypes at
E13.5 and E15.5, which represent times before and after the appearance of the phenotype,
respectively (Figure 3-4).
We next assessed the level of apoptosis by TUNEL assay and staining for activated
caspase 3 at E13.5. As expected, we observed clusters of apoptotic cells in the interdigital
mesenchyme in both genotypes. We also observed an increase in the number of apoptotic
cells in the mutant compared to control digits. At E13.5, there was a 6.9-fold increase in
apoptotic cells in the Atrx(Prx1) cKO (p=0.038, N=4), and a 4.8-fold increase in the
number of cells containing activated caspase 3 (p=0.004, N=4) (Figure 3-5). At E15.5
there was a significant 3.8-fold increase in apoptotic cells in the Atrx(Prx1) cKO
(p=0.028, N=3)(Figure 3-S2).

3.3.4

Increased Level of γ-H2AX foci in Atrx-null Embryonic Limb
Bud Mesenchyme and Chondrocytes.

As we and others previously reported increased levels of DNA damage upon loss of Atrx
(Huh et al., 2012; Watson et al., 2013), we examined Atrx(Prx1) cKO forelimbs for
evidence of DNA damage. We stained embryonic limb cryosections from E12.5 to E17.5
with an antibody against phosphorylated histone 2A family member X (γ-H2AX), a
marker of DNA double strand breaks. Confocal imaging and quantification at E13.5 and
E15.5 showed a significant increase in the number of cells harbouring γ-H2AX foci in the
forelimb mesenchyme of Atrx(Prx1) cKO mice (Figure 3-6A,B) and cartilaginous digit
rays (Figure 3-S3). To confirm this result, we co-stained cryosections with 53BP1, a
DNA damage response protein that promptly re-localizes to damaged sites. We observed
a higher number of 53BP1 foci in mutant forepaws that largely overlapped with the γH2AX foci (Figure 3-6C). In the limb buds of heterozygous female embryos, Atrx is
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Figure 3-4 Proliferation is unchanged in the Atrx(Prx1) cKO embryonic limb bud.
Immunofluorescent stains for the S-phase marker Ki67 in embryonic day 13.5 (A) and
15.5 (B) forelimb cryosections. More Ki67+ cells are present in the highly proliferative
distal tip as compared to the differentiated digit ray, but no significant change is observed
between genotypes. Scale bar: 20 µm, Error bars = SD, N = 4.
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Figure 3-5 Cell death is increased in the Atrx(Prx1) cKO embryonic limb bud.
Fluorescent TUNEL and activated caspase 3 stains of frozen sections for embryonic day
13.5 forelimbs. (A) At E13.5, more TUNEL positive nuclei are observed per digit tip in
mutant forelimb sections (N=4). (B) Atrx(Prx1) cKO embryonic limb buds contain
significantly more cells containing activated caspase 3 (N=4). Scale bar: 200 µm Error
bars = SEM. * p < 0.05 (students T-test)
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Figure 3-6 ATRX-deficient limb buds have increased levels of DNA double strand
breaks
(A) Immunofluorescent stains for the phosphorylated histone gamma-H2A.X (γ-H2AX )
in embryonic day 13.5 forelimb sections. γ-H2AX signal frequently appears in the
mutant nuclei as a single bright focus which is absent in the control. Expression of γH2AX was similar between distal phalange tips and differentiated digit rays. Scale bar:
50 µm. N =4 (B) Immunofluorescent stains for γ-H2AX in embryonic day 15.5 forelimb
section demonstrating persistence of the γ-H2AX foci within the nucleus of Atrx(Prx1)
cKO cells. Scale bar: 50 µm. N =4 (C) Immunofluorescent stains for γ-H2AX and 53BP1
in embryonic day 13.5 forelimb sections. Sites of γ-H2AX signal co-localise with 53BP1
in all parts of the forelimb. Scale bar: 50 µm (D) Immunofluorescent staining for Lamin
B and γ-H2AX, demonstrating large DNA damage foci located in close proximity to the
nuclear lamina. Scale bar: 10 µm (E) Quantification of distance between the center of the
bright γ-H2AX focus and the nearest nuclear lamina.
Error bars = SD, * p < 0.05 Student's T-test
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deleted in approximately 50% of cells, as expected from a random pattern of Xinactivation. Forelimb tissue of heterozygote female mice at E13.5 had γ-H2AX foci in
17% of cells (Figure 3-S4), but less than 2% of ATRX+ cells contained DNA damage
foci. These findings suggest that DNA damage incurred is due to a cell-autonomous
effect of Atrx loss.
Surprisingly, the γ-H2AX staining in Atrx(Prx1) cKO cells appeared as one discrete,
bright focus in the nucleus (Figure 3-6D). Moreover, staining of the sections with an
antibody that recognizes lamin B demonstrates that the large majority of the DNA
damage foci are located in close proximity to the nuclear lamina, which was confirmed
by measurements of distance of the foci to the nuclear lamina using confocal microscopy
(Figure 3-6D, E). Interestingly, no increase in γ-H2AX staining was observed in male
embryos when the Atrx gene was inactivated using the cartilage-specific Col2-Cre driver
line (Figure 3-S5).

3.3.5

Atrx-deficient Forelimb Mesenchyme cells are not
Hypersensitive to Hydroxyurea Treatment.

Control and Atrx(Prx1) cKO embryonic forelimbs were cultured and treated with
increasing concentrations of the fork-stalling compound hydroxyurea (HU) for 24 h to
determine whether ATRX-deficient limb bud cells are more sensitive to replication stress,
as has been reported for other cell types (Leung et al., 2013; Seah et al., 2008; Watson et
al., 2013). 24 or 48 h after end of treatment, cell viability was assessed by MTT assays. γH2AX staining increased in a dose-dependent manner in response to HU treatment.
However, we observed that cells of all genotypes showed a similar reduction in viability
in response to HU (Figure 3-S6).

3.3.6

Reduced Forelimb Function and Shorter Stride Length in
Atrx cKO Mice

To determine whether the brachydactyly phenotype observed in the Atrx(Prx1) cKO
(Figure 3-7A) had any functional consequence, we evaluated various parameters of
forelimb function and gait. We found that the maximal grip strength values of adult
Atrx(Prx1) cKO mice were significantly lower than those of control littermates
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Figure 3-7 Reduced forelimb function at one year of age in Atrx(Prx1) cKO mice
(A) Characteristic forelimb appearance of Ctrl and Atrx(Prx1) cKO mice showing
shortened fingers and a smaller paw. (B) Forelimb grip strength of control and mutant
adult mice. Mutant mice exert significantly less force with their forelimbs before
releasing the bar. Error bars = SD, N=5 p < 0.05, Student's T-test (C) Quantification of
mouse gait parameters. Stride length of the fore- and hind-paws is shorter in Atrx(Prx1)
cKO mice. Error bars = SD, N=5 p < 0.05, Student's T-test
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(Figure 3-7B), reflecting a loss of forelimb function that coincides with shortening of the
phalanges. Next, we utilized the Catwalk system to analyse gait parameters in freely
ambulating mice. The spatial relationship between paw prints was used to determine
stride length and walking pattern. Forelimb stride length was reduced in Atrx(Prx1) cKO
mice compared to control littermates (45.65 mm ± 3.06 mm vs 50.09 mm ± 2.64 mm, p <
0.05,N=5 pairs Students T-test). Hind limb stride length was also reduced (45.45 mm ±
2.94 mm vs 50.23 mm ± 2.93 mm, p < 0.05, N=5 pairs Students T-test), despite the
absence of any morphological changes in the hind limbs of mutant mice (Figure 3-7C).
Conversely, the regularity index of footfall patterns did not vary between genotypes,
indicating that mutants had a normal walking pattern and showed no instability or
impairment in gait (Figure 3-S7A,B). Additionally, there was no significant variation in
base of support or swing duration when walking (Figure 3-S7C,D).

3.4

Discussion

This study shows that loss of ATRX in early limb mesenchyme leads to brachydactyly
and smaller digits, associated with DNA damage and apoptosis. Specifically,
brachydactyly occurred as shortening of the distal phalanges of the forelimb, beginning at
E15.5. Atrx has previously been deleted in the early developing cartilage without
phenotypic consequence, raising questions about the cell types responsible for the
skeletal abnormalities in ATR-X patients (Solomon et al., 2009). We demonstrate here
that loss of ATRX in mesenchymal precursor cells prior to differentiation into cartilage
gives rise to one skeletal phenotype observed in ATR-X syndrome patients. Furthermore,
our model suggests that apoptosis in response to DNA damage is a new molecular and
cellular mechanism responsible for brachydactyly. This is distinct from other forms of
brachydactyly, many of which are due to mutations in key developmental signalling
genes, such as components of the hedgehog, Wnt or TGFbeta family pathways or Hox
genes (Gao et al., 2009; Minami et al., 2010).
This model, unlike loss of ATRX in developing cartilage (Solomon et al., 2009), deletes
Atrx early in limb development and leads to a more severe phenotype. This suggests that
ATRX function is more critical in mesenchymal precursor cells than in differentiated
chondrocytes. In support of this model, we did not observe any DNA damage in our
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cartilage-specific ATRX-deficient mice. In our experiments, the distal portions of the
digit are first to show significant shortening, and during post-natal development the
affected mice do not catch up to littermates.
One question addressed by this study is whether loss-of-function of ATRX has a direct
effect in the developing skeleton. The observed brachydactyly is likely to be a direct
effect of ATRX in the limb bud, rather than a secondary effect of ATRX loss in another
tissue, as this model uses a cre-lox system specific for the early forelimb. The hind limbs
were not affected in the mutant mice, which was expected since Prx-cre activity is limited
in the hind limb compared to the forelimb (Logan et al., 2002). Our findings demonstrate
that not only does loss of ATRX in the forelimb mesenchyme have direct effects on
skeletal development, but it also has wide-reaching effects on the physiology of the adult
animal. Adult mutant mice retain shortening on the distal phalanges, and have visibly
smaller paws than control littermates. Furthermore, the digits in the paws are not flexed
normally, and have reduced function. These mice have weaker grip strength due to the
smaller digits, an indication that the shorter fingers are more difficult to bend and have
limited strength. The reduced function is also observed in the gait of these animals, in
which they maintain a normal pattern of walking but take significantly shorter steps.
Prior to the appearance of the phalange shortening, mutant mice display widespread DNA
double-strand breaks in limb bud tissue as identified by increased γ-H2AX staining.
Previous studies have shown that ATRX is required for maintaining structural integrity of
telomeres and depletion of ATRX leads to telomere instability and fusions (Watson et al.,
2013; Wong et al., 2010). However, in contrast to other models of ATRX deficiency, the
DNA damage seen in limb bud cells in our study exhibit two specific characteristics.
First, DNA damage occurs as one discrete dot in the nucleus, close to the nuclear
periphery. This single focus is unusual, as γH2AX-postive DNA damage has a more
speckled or diffuse appearance in other ATRX-null tissues (Huh et al., 2012; Watson et
al., 2013; Wong et al., 2010). It is not clear at this point whether the signal we observe is
from one chromosomal site or from an amalgamation of several damaged sites at the
nuclear lamina. It has been shown in budding yeast that numerous domains containing
DSBs can merge into one aggregate in the nucleus. In this manner, persistent DSBs and

88

telomeres can be sequestered to the periphery of the nucleus, a common location for
dangerous and damaged DNA elements in the genome (Aten et al., 2004; Oza et al.,
2009; Schober et al., 2009; Soutoglou et al., 2007). Large DNA damage foci have also
been observed in pig skin cells following gamma irradiation: the damage appears initially
at multiple sites but after 70 days can be seen as one or a few large nuclear foci (Ahmed
et al., 2012). In mouse embryonic fibroblasts, the inner nuclear envelope proteins SUN1
and SUN2 have been shown to be important in DNA damage response and possibly play
a role in nonhomologous end joining repair (Lei et al., 2012). Mammalian nuclear lamins
themselves are also important in nuclear organization and cell-cycle response to DNA
damage (Johnson et al., 2004). Thus, persistent DSBs within the nuclei of ATRXdepleted forelimb cells might be transported to the nuclear periphery, either for
sequestering from the rest of the genome, repair or activation of cell cycle arrest.
A second unusual feature of ATRX-deficient limb bud cells is that they are not
hypersensitive to HU treatment while ATRX deficiency in neuroprogenitors and other
cells leads to increased sensitivity to replication stress-inducing drugs (Conte et al., 2012;
Watson et al., 2013). In the developing forelimb, the most affected cells at the distal end
of the digit are highly proliferative and contribute to lengthening of the digits. Thus, one
could have expected these cells to be very sensitive to replication stress, but our data
show that loss of ATRX does not increase the sensitivity of these cells to HU treatment.
In addition, the level of cell death observed in mutant digits is markedly lower than that
seen in the ATRX null brain (Huh et al., 2012; Leung et al., 2013; Watson et al., 2013).
The specific connection between loss of ATRX and DNA damage in limb bud cells
therefore remains to be explored.
Our studies add to recent publications implicating epigenetic regulators in brachydactyly
and skeletal development. Heterozygote mutations in the HDAC4 gene, encoding a
histone deacetylase, have been identified as a cause of brachydactyly type E, and
translocation of a gene encoding a long non-coding RNA results in brachydactyly type E
as well (Maass et al., 2012; Williams et al., 2010).

Maybe most closely related to our

studies, loss of the single-stranded DNA binding protein OBFC2B leads to growth delay
and skeletal abnormalities due to accumulation of γ-H2AX and apoptosis in the pre-
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cartilage condensations (Feldhahn et al., 2012). While OBFC2A, a homologue, is
required in many other cell types (Feldhahn et al., 2012), it appears that the skeletal
lineage has developed specific methods of dealing with increased levels of DNA damage
during development. A genetic assault, such as the loss of ATRX, is still hazardous in the
developing forelimb, but not to the same degree as in the CNS. Thus, our results suggest
that the role of ATRX varies between cell types, or alternatively that different cell types
utilize distinct mechanisms to maintain genomic integrity.
In summary, by using tissue-specific deletion of Atrx, we have recapitulated part of the
skeletal phenotype of ATR-X syndrome and found a direct role for ATRX in preventing
DNA damage and maintaining cell survival in the highly proliferative developing digit
mesenchyme. Our data suggest that DNA damage-induced apoptosis of limb
mesenchymal cells can result in brachydactyly, a mechanism that might be functionally
relevant to additional brachydactylies and other skeletal dysplasias.
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3.5

Supplementary Figures

Supplementary Figure 3-1 Atrx(Prx1) cKO mice are born at normal weight.
No significant difference was observed between the weight of mutant and control
littermates at birth. N = 5, Error bars = SD.
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Supplementary Figure 3-2 ATRX-deficient limb buds have increased levels of DNA
double strand breaks at E15.5
At E15.5 there is significantly more apoptotic nuclei per digit in the Atrx(Prx1) cKO
Scale bar: 200 µm. N=3, * = p < 0.05 by Student's T-test,. Error bars = SEM.
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Supplementary Figure 3-3 ATRX-deficient digit rays have increased levels of DNA
double strand breaks
Confocal imaging and quantification at (A) E13.5 and (B) E15.5 showed a significant
increase in the number of cells harbouring γ-H2AX foci in the cartilaginous digit rays.
Scale bar: 50 µm. N=4, * = p < 0.05 by Student's T-test,. Error bars = SD.
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Supplementary Figure 3-4 Heterozygous female Atrx(Prx1) cKO female mice
demonstrate DNA damage foci preferentially in ATRX-depleted cells
DNA damage is associated with ATRX-null cells in heterozygote female mice.
Representative images of immunofluorescence staining of cells for ATRX (green) and γH2AX (red). Scale bar: 10 µm. Approximately half (44%) of the cells retained ATRX,
but almost all the cells containing γ-H2AX foci were ATRX negative.
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Supplementary Figure 3-5 γ-H2AX nuclear foci are not present in the nuclei of
chondrocytes in cartilage-specific ATRX-deficient mice.
Ctrl and Atrx(Col2) cKO forelimb chondrocytes do not demonstrate large nuclear γH2AX nuclear foci, unlike Atrx(Prx1) cKO mice. Scale bar: 50 µm
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Supplementary Figure 3-6 ATRX-deficient forelimb cells are not hypersensitive to
hydroxyurea treatment.
Cultured cells from Ctrl and Atrx(Prx1) cKO embryonic forelimbs were treated with
increasing concentrations of the fork-stalling compound hydroxyurea (HU) for 24h and
allowed to recover for 1 day (A) or 2 days (B). Cells of all genotypes show similarly
reduced viability after HU treatment, and ATRX-null cells did not display increased loss
of viability.
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Supplementary Figure 3-7 Gait parameters of instability and impairment are
unaffected in Atrx(Prx1) cKO mice.
(A) Regularity index of mouse gait was unchanged between genotypes. (B) Step patterns
of Ctrl and Atrx(Prx1) cKO mice, demonstrating that both mice mainly used a normal
trotting gait (Ab pattern, in which diagonal legs move together and in phase). (C) Base of
support between limbs was unaffected between genotypes. (D) All paws demonstrated a
similar swing speed, indicating that each foot was in the air for a similar amount of time
and no specific foot was being favoured. No difference in swing speed was observed
between genotypes. Error Bars = SD, N = 5
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Chapter 4

4

Loss of Atrx Does Not Confer Susceptibility to
Osteoarthritis

The chromatin remodelling protein ATRX is associated with the rare genetic disorder
ATR-X syndrome. This syndrome includes developmental delay, cognitive impairment
and a variety of skeletal deformities. Atrx plays a role in several basic chromatinmediated cellular events including DNA replication, telomere stability, gene
transcription, and chromosome congression and cohesion during cell division. We have
used a loss-of-function approach to directly investigate the role of Atrx in the adult
skeleton in three different models of selective Atrx loss. We specifically targeted deletion
of Atrx to the forelimb mesenchyme, to cartilage and to bone-forming osteoblasts. We
previously demonstrated that loss of Atrx in forelimb mesenchyme causes brachydactyly
while deletion in chondrocytes had minimal effects during development. We now show
that targeted deletion of Atrx in osteoblasts causes reduced body size but does not
recapitulate most of the skeletal phenotypes seen in ATR-X syndrome patients. In adult
mice from all three models, we find that joints lacking Atrx are not more susceptible to
osteoarthritis, as determined by OARSI scoring and immunohistochemistry. These results
indicate that while Atrx plays limited roles during early stages of skeletal development,
deficiency of the protein in adult tissues does not confer susceptibility to osteoarthritis.

4.1

Introduction

Osteoarthritis (OA) is a degenerative joint disease to which there is no cure. It is
characterized by the degeneration of articular cartilage and changes in other joint tissues
including subchondral bone and synovium. Cartilage is maintained by a balance of both
anabolic and catabolic activities. OA occurs when these processes are in disequilibrium
and catabolism outweighs anabolic repair (Goldring et al., 2009). Osteoarthritis can be
triggered by many factors including diet, injury, strain and genetic abnormalities (Aigner
et al., 2007; Aspden, 2008; Aspden, 2011; Goldring et al., 2009; Wang et al., 2011).
However, the molecular mechanisms driving disease onset and progression are
incompletely understood.
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Alterations in epigenetic mechanisms affecting gene expression have been previously
reported in articular chondrocytes (Aspden, 2008). A recent study has linked genetic
variants of DOT1L, an evolutionarily conserved histone methyltransferase required for
chondrogenic differentiation, to increased susceptibility to osteoarthritis (Castaño
Betancourt et al., 2012). Alterations in expression of histone acetylases and deacetylases
has also been associated with arthritis (Huber et al., 2007). The ageing-related gene SirT1
is of particular interest, as it codes for a protein capable of deacetylating histones and
other proteins (Dvir-Ginzberg et al., 2013). Expression of SirT1 in chondrocytes is
associated with increased survival and down-regulation of the proapoptotic protein
PTP1B associated with OA (Gagarina et al., 2010). Age-related diseases, as well as
normal aging, are frequently influenced by changes in chromatin structure, leading to
deleterious effects on cell and tissue function (Sedivy et al., 2008).
Hypomorphic mutations causing dysfunction of the ATRX chromatin remodeling protein
can lead to various skeletal deformities, including dwarfism, spine deformities and
malformation of the hands and feet (Gibbons et al., 1995a; Gibbons et al., 2000). These
defects occur in conjunction with developmental delay, psychomotor and mental
retardation, distinct facial features, urogenital abnormalities and α-thalassemia (Gibbons
et al., 1995a). Radiological analysis in a few cases has shown that individuals with ATRX
mutations show generalised retardation in skeletal maturation (Gibbons et al., 1995a).
ATRX contains two conserved domains where the majority of disease-related mutations
are located. The N-terminus contains a plant homeodomain-type (PHD-type) zinc finger
that acts as a histone reader module by mediating binding to specific post-translational
modifications on histone H3 (Dhayalan et al., 2011; Otani et al., 2009; Wong et al.,
2010). Towards the C-terminus, ATRX contains a Sucrose Non Fermenting 2 (SNF2)type DNA-dependent ATPase domain that functions to remodel chromatin (Eisen et al.,
1995; Gibbons et al., 1995b; Picketts et al., 1996). The functional full-length protein has
been shown to play an important role in chromosomal integrity, maintaining organization
and sister chromatid cohesion during cell division (Ritchie et al., 2008).
While there have been various developmental studies that show severe effects of tissuespecific Atrx deficiency (Bérubé et al., 2005; Garrick et al., 2006; Huh et al., 2012;

104

Medina et al., 2009) cartilage-specific inactivation of the Atrx gene in mice does not
result in major phenotypes. (Solomon et al., 2009). On the other hand, loss of Atrx in the
forebrain and pituitary of mice leads to features of aging including low bone mass, loss of
subcutaneous fat, and clouded ocular lenses (Watson et al., 2013), prompting us to ask
whether Atrx is important in aging skeletal elements and joints. Since Atrx is highly
expressed in chondrocytes (Solomon et al., 2009), it could be a potential epigenetic
regulator of specific genes involved in healthy cartilage maintenance and its loss may
lead to diseases such as osteoarthritis. This study examined the role of ATRX in three
models of Atrx deficiency and assessed the onset and progression of osteoarthritis using
Osteoarthritis Research Society International (OARSI) histopathology guidelines and
molecular markers of OA.

4.2
4.2.1

Materials and Methods
Animals

All animals studies were approved by the Council on Animal Care at the University of
Western Ontario, protocol 2007-045.
The cartilage-specific Atrx depleted Atrx (Col2) cKO (AtrxCol2) mice were generated as
described previously (Solomon et al., 2009). Both wild-type and AtrxCol2 mice were
maintained until the age of two years. Bone-specific Atrx depleted mice were generated
using an osteoblast-specific cre mouse (Liu et al., 2004) to generate Atrx(Col1) cKO
(AtrxCol1) mice. Forelimb specific deletion of Atrx was generated as described previously
using the forelimb-specific Prx1-cre to generate Atrx (Prx1) cKO mice (AtrxPrx) (Logan
et al., 2002; Solomon et al., 2013).
PCR genotyping from ear tissue for cre and Atrx as described previously (Solomon et al.,
2009). Atrxfloxed and Cre alleles were confirmed as previously described (Seah et al.,
2008; Terpstra et al., 2003). A 1.5 kb fragment containing the neo cassette within the Atrx
floxed

allele

was

identified

with

one

set

of

primers

(5′-

GATCGGCCATTGAACAAGAT-3′ and 5′-ATA GGT CGG CGG TTC AT-3′) whereas
the wild-type allele was detected with another set (5′-CCC GAG TAT CTG GAA GAC
AG-3′and 5′-ATA GGT CGG CGG TTC AT-3′). Primers (5′-CCT GGA AAA TGC TTC
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TGT CC-3′) and (5′-CAG GGT GTT ATA AAC AAT CCC-3′) were used to amplify a
common 300 base pair fragment for all three versions of the cre gene. PCR conditions
were as follows: 95°C for 3 min (95°C for 30 s, 55°C for 45 s, and 72°C for 1 min) × 36,
72°C for 10 min for Cre , 95°C for 3 min (95°C for 30 s, 55°C for 1 min, and 72°C for 5
min) × 36, 72°C for 10 min for Atrx.

4.2.2

Histological Staining of Bone and Joint Sections

Limbs were dissected from Atrx-depleted mice upon sacrifice and processed for
histological analyses by Picrosirius Red, safranin-O and immunohistochemical staining
as described (Appleton et al., 2007; Wang et al., 2007; Yan et al., 2010). For histological
analyses, specimens were fixed in 4% paraformaldehyde, decalcified with 5% EDTA,
paraffin embedded and sectioned at 5 µm. For immunohistochemistry, samples were
examined in dewaxed paraffin–embedded sections. Following dehydration, sections were
blocked in hydrogen peroxide followed by 5% goat serum, and incubated with a
polyclonal rabbit antibodies to MMP13 (Santa Cruz), aggrecan fragments (MMP cleaved,
N-terminus FFGVG neoepitope, Millipore), Atrx (Prestige Antibodies, Sigma-Aldrich) or
type II collagen (Santa Cruz) according to manufacturer's instructions. Following
overnight incubation at 4°C sections were incubated with HRP–conjugated secondary
goat antibody against rabbit IgG and detected by staining with DAB (Dako). To quantify
trabecular area, sections were stained for one hour in 0.1% Picrosirius Red. Using imageJ
software, an area of interest (AOI) was set from the chondro-osseous junction to 200 µm
below the growth plate in the trabecular bone area of the mineralised zone, as described
previously (Watson et al., 2013).

4.2.3

Histological End-Stage Analysis

Sections from a minimum of three independent litters were stained with Safranin-O and
fast green, and graded according to the Osteoarthritis Research Society International
(OARSI) scoring system (Glasson et al., 2010). OA scores were assigned by two blinded
observers and total score was calculated by averaging the grade and stage values for each
slide (a minimum score of 0 represents no OA degradation and a score of 6 represents the
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maximum degree of OA). Maximal OARSI grade was determined for each joint based on
the surface displaying the highest OARSI score in each section.

4.2.4

Skeletal Stains and Measurements

Live mice were weighed at P0 and P21. Euthanized animals were skinned and
eviscerated, fixed overnight in 95% ethanol followed by overnight fixation in acetone for
Alizarin Red/Alcian Blue staining. Whole skeletons were stained for 7–10 days (0.05%
Alizarin Red, 0.015% Alcian Blue, 5% acetic acid in 70% ethanol) (Wang et al., 2007).
Skeletons were cleared in 2% w/w KOH. Bones were imaged on an Olympus SP-57OUZ
camera. Limb bones and skulls from at least three independent littermate pairs were
measured using a dissecting microscope with a ruler.

4.2.5

Microcomputed Tomography

Male AtrxCol1 and control littermate mice were sacrificed at weaning (21 days of age),
skinned and eviscerated, followed by fixation in formalin. Whole bodies were imaged
using a scanner (eXplore Locus MicroCT; GE Healthcare) at 120 kV and 20 mA, with a
0.154 mm3 voxel resolution with a total of 900 slices per scan. Bone mineral density
(BMD), cortical thickness and trabecular numbers were calculated using the Microview
3D visualization and analysis software (MicroView, Version 2.1.2, GE Healthcare
Biosciences) (Ulici et al., 2009).

4.2.6

Osteoblast Isolation and Differentiation

Calvarial cells were isolated from 8-10 day old AtrxCol1 mice using sequential collagenase
digestion, as previously described (Bellows et al., 1989; Panupinthu et al., 2008). Briefly,
calvaria from control and mutant mice were dissected, scraped clean of mesenchyme by
micro dissection, and digested through three changes of collagenase. Pooled cells from
the latter two changes of collagenase were plated on six-well plates at a density of 1.5 ×
104 cells/cm2 in culture medium. After three days, cells were transferred to high density
micromass cultures in 24-well plates, with each well containing 5 × 104 cells in a 150-µl
drop of culture medium. After 12 hours, culture medium was added to the micromass

107

cultures. Culture media was supplemented with 50 µg/ml ascorbic acid and 2 mM βglycerophosphate, and cultures were maintained for up to 4 weeks.

4.2.7

Analyses of Alkaline Phosphatase Activity and Mineral
Deposition

Calvarial micromass cultures were fixed in 4% PFA overnight at 4°C. Alkaline
phosphatase activity was assayed using a mixture of 1.25 mM Fast Red B salt in 0.1 M
Tris-HCl, pH 8, and 0.25 mM naphthol AS-MX phosphate, protected from light for one
hour. Mineralised nodules were visualised following ALP staining using 2.5% silver
nitrate solution for 1 h with exposure to light.

4.3
4.3.1

Results
Skeletal Phenotypes of Adult Atrxcol2 Mice

To determine if Atrx played a direct role in skeletal development, mice with cartilagespecific inactivation of Atrx were generated utilizing the Cre-LoxP system. Female mice
previously engineered with LoxP sites flanking exon 18 of Atrx (Bérubé et al., 2005)
were crossed with male mice expressing Cre recombinase under the control of the mouse
collagen II (Col2a1) promoter (Terpstra et al., 2003). Cre-positive male offspring lacked
Atrx in the developing cartilage but developed normally with only minor defects in
skeletogenesis (Solomon et al., 2009). AtrxCol2 mice were born at normal Mendelian ratios
and did not demonstrate defects in skeletal size or growth plate morphology at birth or
weaning (Solomon et al., 2009).
To examine if embryonic depletion of Atrx in the developing cartilage contributes to
reduced cartilage integrity later in life, two-year old AtrxCol2 mice were examined for
signs of osteoarthritis and other skeletal defects. No significant weight difference was
observed between control and mutant mice at two years of age (Ctrl: 36.57 ± 6.38 grams,
AtrxCol2: 31.56 ± 8.51 grams). Paraffin sections of knee joints from control and mutant
AtrxCol2 mice were assessed for osteoarthritis using the OARSI histopathology guidelines
(Glasson et al., 2010) on tissue sections stained for cartilage proteoglycan with safraninO. In both genotypes, cartilage appeared relatively healthy with only minor degeneration.
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Maximal OARSI score of the knee joint was not different in controls compared to
AtrxCol2 mice. Control mice had a maximal knee score 1.70 and mutant mice had a
maximal score of 1.53 (p= 0.89) (Figure 4-1A). AtrxCol2 mice did not show a significant
increase in fibrillation and fissuring of the articular surfaces. Absence of ATRX protein
in articular cartilage was confirmed by immunohistochemistry using a rabbit anti-ATRX
antibody (Prestige Antibodies, Sigma-Aldrich) on knee joint sections (Figure 4-1B).

4.3.2

Mmp13, Aggrecan Fragment and Type II Collagen Levels
are Normal in Atrxcol2 Mice

Several molecular changes have been associated with OA.

MMP13 (matrix

metalloproteinase 13) plays a catabolic role in the progression of cartilage degeneration
and cleaves collagens, gelatin, and aggrecan (Fosang et al., 1996; Wang et al., 2011).
Aggrecan is an extracellular matrix protein and its degradation into fragments is
accelerated in OA (Pollard et al., 2008). Finally, type II collagen is cleaved by a number
of MMPs including MMP13. In arthritic joints, loss of the collagen matrix is accelerated,
leading to erosion of the articular surface (Glasson et al., 2010).
Using immunohistochemistry, we detected no visible difference in MMP13 expression in
tibia articular cartilage between control and mutant mice.

MMP13 expression was

quantified as a percentage of MMP13 positive cells to total cells in 1000 pixel wide
sections of articular cartilage. Statistical analysis confirmed that there was no significant
difference in MMP13 levels between mutants and control littermates (35.7% vs. 39.3%
respectively, p= 0.451) (Supplementary Figure 4-1A,B). Tibial aggrecan fragment levels
was also not altered between control and AtrxCol2 mice as revealed by IHC analysis.
Control and knockout mice were not significantly different in the percentage of aggrecan
fragment-positive cells versus total cells in articular cartilage(34.02% vs. 22.87%, p=
0.074) (Supplementary Figure 4-1C, D). Upon immunostaining for Collagen II, we
observed that the mean thickness of the collagen II-positive zone of the articular cartilage
was not significantly different when comparing the tibiae of control and mutant mice
(87.993 µm vs. 90.065 µm, p= 0.837). There was also no significant difference in the
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Figure 4-1 Characterisation of joint morphology in two year-old AtrxCol2 mice.
A) Knee sections were stained with safranin-O to detect the presence of proteoglycans.
Minor fibrillation and fissuring of the tibial and femoral articular surfaces was observed
in both genotypes, demonstrating mild osteoarthritis in both genotypes. OARSI scoring
confirmed the absence of significant differences between genotypes. Sections Scale bar =
96 µm. B) Immunohistological staining of articular cartilage, demonstrating that ATRX
protein is present in normal aged articular cartilage, but absent from the nuclei of mutant
chondrocytes. Scale bar = 48 µm.
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thickness of collagen II positive articular cartilage between the femurs of controls and
mutant mice (82.080 µm vs. 81.142 µm, p= 0.923)(Supplementary Figure 4-1E,F).

4.3.3

Loss of ATRX During Forelimb Development does Not Lead
to Forelimb Osteoarthritis

AtrxPrx1 mice were previously characterised and display brachydactyly and abnormal gait
(Solomon et al., 2013). We now examined the joints to determine if structural variations
in the limb might alter kinematics and thus lead to joint disease. Forelimb and hindlimb
joints from AtrxPrx1 mice were examined for osteoarthritis at two years of age (Figure 42). Although the forelimbs of AtrxPrx1 are derived from ATRX-depleted mesenchyme, no
difference was seen in the articular cartilage of the forelimb joint (Figure 4-2A). Control
animals had a mean score of 1.32 and mutants had a mean score of 1.50 (p= 0.82).
Similar to other models of ATRX loss in the skeleton, AtrxPrx1 mice do not demonstrate
knee osteoarthritis, with a maximal OA score of 2.18 in mutant knees and 1.78 in control
littermates (p=0.69) (Figure 4-2B). Loss of ATRX in articular cartilage derived from
ATRX-deficient forelimb mesenchyme was confirmed by staining with IHC (Figure 42C).

4.3.4

Atrxcol1 Mice Exhibit Reduced Growth Without Growth Plate
Abnormalities

To examine the role of ATRX in bone-forming osteoblasts, the osteoblast-specific
Col1a1-Cre driver line was utilized (Liu et al., 2004). AtrxCol1 mice were born at normal
Mendelian ratios, showing that loss of Atrx in the osteoblast does not lead to embryonic
or perinatal lethality (Figure 4-3A). In the neonatal period AtrxCol1 mice exhibited
reduced growth compared to their control littermates, and at weaning they were smaller
and had shorter limbs (Figure 4-3B). Bone length measurements of the appendicular
skeleton showed that the forelimb long bones of AtrxCol1 mice (ulna, radius, humerus) are
significantly shorter than those of controls, while the shortening of femur and tibia was
not statistically significant (Figure 4-3C).
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Figure 4-2 Characterisation of joint osteoarthritis in AtrxPrx1 mice.
A) Knee and elbow sections were stained with safranin-O to detect the presence of
proteoglycans. No change was observed in the articular surfaces was observed in k of
control or mutant mice, and no difference was seen between genotypes. Scale bar = 96
µm. B) Integrity of the knee was similar in control and mutant mice, with minor
fibrillation and fissuring of the articular surface (Arrows). C) Immunohistological
staining of articular cartilage from the elbows of mice, demonstrating that ATRX protein
is present in normal aged articular cartilage, but absent from the nuclei of chondrocytes
derived from ATRX deficient forelimb mesenchyme. Scale bar = 48 µm.
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Figure 4-3 AtrxCol1 mice exhibit reduced growth without growth plate abnormalities
A) Mice lacking Atrx in osteoblasts are born at normal Mendelian ratios. B) Overall
skeletal morphology of AtrxCol1 examined by alican blue/alizarin red stain reveals reduced
overall size and shortened limbs. C) Longitudinal measurements of the bones of the axial
skeleton demonstrate that all bones in the mutant are shortened, and forelimb bones show
significant shortening compared to controls N=5 (* p<0.05) Error bars = SD. D)
Mineralised trabecular bone area below the growth plate at weaning is not different
between genotypes upon visualization of sections stained with picrosirius red staining.
Scale bar = 192 µm. E) AtrxCol1 mice are smaller by body weight compared to littermates
at birth, weaning and adulthood. F) IHC staining for Atrx protein demonstrates reduced
Atrx in AtrxCol1 cortical and subchondral bone. Scale bar = 48 µm.
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Histological analysis of long bones by picrosirius red staining did not show any changes
in growth plate morphology or trabecular density between genotypes (Figure 4-3D, and
Supplementary Figures 4-2, 4-3). Additionally, establishment of the secondary
ossification center was not delayed in long bones of 10 day old mutant mice, as
determined by safranin-O staining (not shown). At one year of age, AtrxCol1 mice
remained smaller than control littermates and did not catch up in weight (Figure 4-3E).
Loss of ATRX in bone was confirmed by IHC staining with rabbit anti-ATRX (Prestige
Antibodies, Sigma Aldrich) in cortical and subchondral bones (Figure 4-3F).

4.3.5

Atrxcol1 Mice Have Normal Mineralisation and Circulating
IGF-1

Micro-computed tomography (Micro-CT) analysis was performed at weaning and
showed no changes in endochondral or intramembranous ossifications. Tibias appeared to
have no gross morphological differences (Figure 4A) and trabecular bone mineral density
(BMD) was unchanged between genotypes (Figure 4B) (N = 3, p >0.05). Trabecular
number was also not significantly changed when analysed by Micro-CT (Figure 4C).
IGF-1 promotes longitudinal bone growth and reduced IGF-1 is associated with limb
shortening (Wang et al., 1999). To determine a possible endocrine component to the
growth restriction in AtrxCol1 mice, levels of circulating IGF-1 were measured by ELISA.
This analysis revealed no significant difference in IGF-1 levels between control and
mutant mice (207.433 ± 35.4 ng/ml vs. KO: 252.010 ± 56.8 ng/ml, respectively p =0.17).
To further investigate the role of ATRX in osteogenesis, we compared mineralisation in
calvarial cells from control and AtrxCol1 mice. Unlike long bones, which form through a
cartilage intermediate, calvarial bone forms by intramembranous ossification and does
not contain cartilage. Examination of skeletal preparations from 21 day old mutant mice
revealed no differences in calvarial structure or suture formation (Figure 5A). Mutant
skulls appeared smaller than those of littermates, but were not significantly smaller by
length (p=0.15) or width (p=0.14) (Figure 5B). To analyze mineralisation by ATRXdepleted osteoblasts, calvarial cells in 3D micromass culture were examined.

114

Figure 4-4 AtrxCol1 mice have normal mineralisation
A) Representative tibias from weaned AtrxCol1 showing that there was no gross
morphological differences in the long bones between genotypes. B) No difference in
bone mineral density (p = 0.90) was observed between AtrxCol1 mice and controls. Error
Bars - SD, N=3 C) Trabecular number was unchanged between AtrxCol1 mice compared
with controls (p = 0.46). Micro-CT data were obtained from hind legs using MicroView
3D software . Error Bars - SD, N=3
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Figure 4-5 Ossification is not impeded or delayed by Atrx depletion in osteoblasts.
A) Ossification of the skull is normal in AtrxCol1 mice, and no changes are seen in suture
formation. B) Skull length and width are not significantly affected in AtrxCol1 mice
compared to controls. N=3, Error bars = SD C) Mineralisation of high-density osteoblast
cultures. Control and Atrx-null osteoblasts show mineralised nodules (black) after two
weeks in osteogenic media, and mineralise at similar rates at three and four weeks.
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Osteogenic media was supplemented with β-glycerophosphate and ascorbic acid for a
four-week time course. The extent of differentiation and formation of mineralised
nodules was assayed by alkaline phosphatase and von Kossa staining. While cultures
increased mineralization over the time course as expected, no difference in APase
staining was observed between genotypes at any time over the four-week culture (Figure
4-5C).

4.3.6

Loss of Atrx in Bone Does Not Lead to Osteoarthritis

To determine if loss of ATRX in osteoblasts would lead to joint damage and
osteoarthritis, joints of AtrxCol1 mice were examined for osteoarthritis at one year of age
(Figure 4-6). AtrxCol1 mice expressed the same amount of ATRX in articular cartilage as
control littermates, as expected with this Cre driver line (data not shown). Maximal
OARSI scores of osteoarthritis in the elbows of AtrxCol1 mice were low in both
genotypes; control animals had a mean score of 0.63 ± 0.60 and mutants had a mean
score of 0.67 ± 0.70 (p= 0.92) (Figure 4-6A). Knee osteoarthritis scores were slightly
higher, with control animals having an averaged maximal score of 1.46 for any quadrant
of frontal knee sections and ATRX-deficient animals having a score of 0.67 (Figure 46B). These values were not significantly different (p=0.20).
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Figure 4-6 Characterisation of joint osteoarthritis in AtrxCol1 mice.
A) Knee and elbow sections were stained with safranin-O to detect the presence of
proteoglycans. Fibrillation or fissuring of the articular surfaces was not observed in
elbows of control or mutant mice, demonstrating very mild OA in both genotypes. Scale
bar = 96 µm. B) Joint integrity of the medial surface of the knee was similar in control
and mutant mice. N = 4, Error bars = SD
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4.4

Discussion

Loss-of-function mutations in the human ATRX gene are associated with skeletal defects
and high incidence of dwarfism. Mouse models of ATR-X syndrome have similar
phenotypes, and demonstrate premature aging (Solomon et al., 2013; Watson et al.,
2013). We report that aged mice lacking Atrx in skeletal tissues (AtrxCol2, AtrxCol1, and
AtrxPrx1) show very limited skeletal defects, with no associated increase in osteoarthritis.
AtrxCol2 mice exhibit minimal skeletal defects during development (Solomon et al.,
2009), so it was not completely surprising that cartilage integrity was maintained during
normal aging. Adult AtrxCol2 mice displayed minor fibrillation and loss of proteoglycan in
the articular cartilage, but at equal levels as aged-matched control littermates. Thus, given
the relative stability of Atrx-null articular cartilage, Atrx does not appear to be required
for structural maintenance of articular cartilage.
No phenotype was observed in the AtrxPrx1 mouse, despite biomechanical differences
observed between genotypes leading to stride alterations (Solomon et al., 2013). AtrxPrx1
mice have shortened forelimb digits and reduced forelimb function, but have no
alterations in the hindlimb.
In the present study, we found that loss of Atrx in osteoblasts causes mild but significant
shortening of the limbs. Given the similar, but more severe, dwarfism observed when
Atrx is deleted in the developing forebrain and anterior pituitary (Watson et al., 2013), it
is possible that this dwarfism is due to an indirect effect, because of unspecific Cre
expression. The possibility of an indirect effect is supported by the fact that ex-vivo
cultures of ATRX-null osteoblasts mineralise normally. Evidence suggests that the
Col1a1-cre used in this study is capable of some LoxP recombination in the brain, so
there remains a possibility that part of the dwarfism phenotype may be due to leaky Atrx
recombination in the brain (Scheller et al., 2011). On the other hand, normal circulating
IGF1 levels suggest that reduced skeletal growth is due to disruption of a bone-intrinsic
role of Atrx.
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In previous reports, a direct or indirect role for ATRX in the development of the skeleton
has been characterised (Solomon et al., 2009; Solomon et al., 2013; Watson et al., 2013).
Alterations in the expression of other chromatin-remodelling proteins in the skeleton can
lead to severe malformations (Alvarez-Saavedra et al., 2010; Young et al., 2005). For
example, dominant negative mutations in the SWI/SNF subunit BRG1 reduce levels of
the transcription factor RUNX2, an important regulator of osteogenesis (Young et al.,
2005). However, no equivalent changes were observed in the expression of Runx2 or
other osteogenic genes in Atrx-null calvaria (data not shown). Osteoblast precursors
isolated from AtrxCol1 mice matured in high density micromass culture and formed
mineral at the same rate as cells from control littermates. Finally, trabecular density was
unaffected when examined histologically, as well as by Micro-CT analysis. Therefore, we
conclude that loss of Atrx in osteoblasts does not impede their ability to mineralise tissue.
When Atrx is lost in the developing limb bud, DNA damage is observed as an
accumulation of y-H2AX-positive nuclei in forelimb cells (Solomon et al., 2013). This
single focus co-localises with DNA damage response factor 53BP1 at the nuclear lamina,
and forelimbs lacking Atrx have higher incidence of TUNEL staining (Solomon et al.,
2013). However, loss of Atrx in this model caused only a slight increase in apoptotic cells
compared to other tissues such as brain, trophoblast, muscle and Sertoli cells (BagheriFam et al., 2011; Bérubé et al., 2005; Garrick et al., 2006; Huh et al., 2012). Thus, our
findings suggest that the protective effect of ATRX against DNA damage and replicative
stress is tissue-specific, and that skeletal tissues are more resistant to the effects of Atrx
loss.
ATRX deletion in various skeletal lineages confers only mild, tissue-specific defects and
does not fully recapitulate the skeletal phenotypes of ATR-X syndrome. Furthermore,
there is no increased incidence of joint osteoarthritis and no difference in the progression
of skeletal pathologies in adulthood. Although ATRX mutations are associated with
skeletal defects in humans, the underlying cause is likely indirect due to reduced function
of ATRX in other tissues (Watson et al., 2013). In conclusion, ATRX is important in the
developing skeleton prior to chondrocyte differentiation and during mineralisation, but is
not important for maintenance of adult skeletal tissues.
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4.5

Supplementary Figures

Supplementary Figure 4-1 MMP13, Aggrecan fragment and type II collagen levels
are normal in AtrxCol2 mice.
(A) MMP13 expression is similar in the articular cartilage of AtrxCol2 mice compared to
controls. Representational immunohistochemical stains of articular cartilage in Atrx
mutant and control mice performed on paraffin sections. Scale bar = 200 µm. (B).
MMP13 expression was not significantly changed in AtrxCol2 mice. Analysis was
performed by counting the percentage of MMP13-positive cells in paraffin sections using
representational subsets of tibial articular cartilage. The average percentage of positive
cells per articular surface was 35.7 ± 0.67% for controls and 39.3 ± 14.2% positive cells
for mutants(n= 8). Control and knockout sections were not significantly different (p>

121

0.05). (C) Tibial aggrecan fragmentation is unchanged in AtrxCol2 mice. Representational
stains for aggrecan fragments in control and knockout mice on 5 µm paraffin sections.
Scale bar = 200µm. (D) Tibial aggrecan fragmentation in unchanged in AtrxCol2 mice.
The average number of aggrecan fragment-positive cells in controls was 34.02 ± 5.92%
(Mean ± SEM) (n= 5). The mean percentage of positive cells in knockouts was 22.8 ±
10.65% (n= 8). Mean percentages of aggrecan fragment-positive cells between controls
and knockout tibiae were not significantly different (p> 0.05). (E) The type II collagen positive zone in articular cartilage of knees of control and AtrxCol2 mice.
Immunohistochemistry stains on paraffin knee sections for type II collagen. Scale bar =
200 µm. (F) The thickness of the type II collagen positive zone in the articular cartilage
of the tibia and femur is not different in AtrxCol2 mice. Three measurements of the type II
collagen-positive zone in the tibia and femur were taken. The average tibial thickness of
the collagen 2-positive zone in controls vs. knockout mice was 87.993 ± 8.827 µm vs.
90.065 ± 5.529 µm (Mean ± SEM) (n= 5). The average femoral thickness of the type II
collagen–positive zone in controls and knockout mice was 82.080 ± 8.820 µm vs. 81.142
± 5.084 µm (n= 8). Neither the tibiae nor femurs of control and knockout mice showed
any significant differences (p> 0.05).
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Supplementary Figure 4-2 Growth plate measurements in AtrxCol1 mice.
No significant difference was seen in the length of the resting, proliferating or
hypertrophic zones in long bones in AtrxCol1 or Control littermates at weaning (N = 3
littermate pairs; two-tailed T-test). Error bars = SD.
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Supplementary Figure 4-3 Trabecular area quantification in AtrxCol1 mice.
Quantification of the area of mineralised trabecular area shows that mineralisation is
unaffected in AtrxCol1 mice. No difference in trabecular area below the growth plates in
the tibia, femur or humerus between AtrxCol1 mice and controls (N=3), Error bars = SD
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Chapter 5

5

General Discussion

This thesis presents data on the role of ATRX in the development and disease of the
skeleton. In this thesis I generated three models of ATRX depletion in the mouse
skeleton, and describe physiological and molecular consequences of ATRX loss during
development. Mutations in the human ATRX gene are associated with skeletal
deformities, so I anticipated that these mouse mutants would demonstrate similar skeletal
defects (Gibbons et al., 2000). Additionally, there exists a large body of evidence
demonstrating important roles for chromatin-modifying enzymes, particularly those with
histone modifying or SWI/SNF activity,

in normal development of the skeleton

(Alvarez-Saavedra et al., 2010; Arnold et al., 2007; Hug, 2004; Jensen et al., 2008;
Shapiro et al., 2010; Sun et al., 2009a; Sun et al., 2009b; Vega et al., 2004).
Surprisingly, the only ATR-X phenotype recapitulated by these mouse models was a
shortening of the distal phalanges when Atrx is deleted in the developing forelimb
mesenchyme. Mice lacking ATRX in the cartilage or osteoblasts had only minor defects,
with limited similarities to ATR-X syndrome. In contrast, a mouse model of ATR-X
syndrome in which Atrx is deleted in the forebrain and pituitary demonstrates severe
skeletal defects including growth restriction, low bone mineral density, and reduced
trabecular area (Watson et al., 2013). Collectively, these findings establish that many of
the skeletal phenotypes observed in ATR-X syndrome may not be due to a direct effect of
ATRX loss-of-function in the skeleton, but secondary to defects in the brain or endocrine
system.
Interestingly, these studies revealed a particular and important property of skeletal tissue
to resist DNA damage, or the cell death associated with DNA damage. DNA damage and
genome instability is observed in other tissues when Atrx is deleted, which frequently
results in widespread apoptosis, suggesting skeletal tissues may have some method of
abrogating this outcome (Baumann et al., 2010; Lovejoy et al., 2012; Ritchie et al., 2008;
Watson et al., 2013).
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5.1

Thesis Summary

In chapter two, I observed that loss of ATRX in the cartilage of mice does not lead to
skeletal defects, and conclude that the skeletal deformities in ATR-X syndrome must
arise from cartilage-extrinsic mechanisms. In chapter three, I described a role for ATRX
in maintaining genomic integrity in the mesenchyme of developing forelimb of the
mouse, and demonstrate a digit malformation phenotype similar to ATR-X syndrome
when ATRX is lost. I correlated the DNA double-strand breaks and associated apoptotic
cell death to loss of proliferating digit cells and shortening of the distal phalanges. In
chapter four I report evidence that loss of ATRX, despite its association with genome
instability and premature aging, does not confer susceptibility of osteoarthritis when lost
in skeletal tissues. By examining joint disease phenotypes in three conditional knockout
models, I concluded that there is no direct role for ATRX in the skeleton in the
establishment of osteoarthritis. Additionally, I quantified mineralisation on a mouse
lacking ATRX in osteoblasts, and conclude that ATRX is not required for osteoblast
function.

5.2
Contributions to Current State of Knowledge
Regarding ATRX in the Skeleton
5.2.1

ATRX in Developing Cartilage

In Chapter two, I tested the hypothesis that mice lacking ATRX in developing cartilage
will demonstrate dwarfism and other skeletal defects similar to those observed in humans
with ATR-X syndrome. I quantified the skeletal phenotypes of mice that lack Atrx
expression in cartilage beginning with the onset of cartilage differentiation from
mesenchyme. These mice showed that loss of ATRX in chondrocytes has minimal effects
on skeletal development, and that mice lacking ATRX in cartilage were viable and were
fertile in adulthood. ATRX loss was confirmed at the level of both mRNA and protein,
and shown to have no effect on the expression of important cartilage growth plate genes
such as Sox9 and p57. Conditionally ATRX-deficient mice had normal growth plate
morphology, with no defects in the ratios of resting, proliferating, or hypertrophic cells at
birth or at weaning. These animals demonstrated only a mild delay in the ossification of
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the pelvic girdle, and have none of the associated skeletal phenotypes of ATR-X
syndrome. I concluded that skeletal phenotypes of ATR-X syndrome are likely due to
secondary effects from tissues like the brain or anterior pituitary.

5.2.2

ATRX in Developing Forelimb

In Chapter three, I investigated the development of the appendicular skeleton from
ATRX-deficient mesenchyme. I reported that mice conditionally lacking ATRX in the
forelimb mesenchyme demonstrate specific brachydactyly, characterised by a shortening
of the cartilage anlage during embryonic development and subsequent shortening of the
ossified digit at, and following, birth. While the shortening of distal phalanges persists
into adulthood, there are limited disease phenotypes in this model.

These animals

demonstrate reduced forelimb function, quantified as a significant decrease in forepaw
grip strength. Adult animals have a mild alteration in gait which manifests as shorter
strides, but do not show any major interlimb coordination defects. The brachydactyly
phenotype correlated with increased levels of the DNA-damage marker γ-H2AX, which
appeared as one bright focus within the nucleus of ATRX-deficient embryonic forelimb
mesenchyme and chondrocytes. This γ-H2AX focus was often located at the periphery of
the nucleus, and using 3D confocal microscopy, I determined that this focus of damaged
DNA was frequently located within one micron of the nuclear lamina. I attribute the digit
shortening to an increase in TUNEL-positive apoptotic cell death in proliferating distal
tip of the digit. I propose that some of the hand deformities observed in ATR-X syndrome
may be due to similar cell death in the developing digit, and predict the cell death is
related to the DNA damage associated with loss of ATRX.

5.2.3

ATRX in Developing Bone

In Chapter four, I describe a model of ATRX-deficiency in mineralising osteoblasts,
which leads to mild dwarfism but does not cause defects in bone mineral formation
during development or in vitro. Although these mice have shortened limbs, this
phenotype does not fully recapitulate the variety of skeletal deformities seen in human
cases of ATRX depletion. These animals do not show premature aging or the defects in
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bone mineral density and trabecular number seen in mice lacking ATRX in the forebrain
and anterior pituitary.

5.2.4

Secondary Effects of ATRX on the Skeleton

There are many reasons to expect a skeletal phenotype in a model of ATRX-deficiency.
Firstly, mutations to ATRX are associated with a wide variety of severe pathologic
skeletal phenotypes in humans. These include short stature, spinal deformities, clubbed
foot, tapered or conical fingers, and delayed bone age (Gibbons et al., 2000). Secondly,
genes with similar epigenetic properties to ATRX such as MeCP2, HDAC4 and NIPBL are
also associated with skeletal deformities in humans and defective skeletal development in
related mouse models (Alvarez-Saavedra et al., 2010; Kawauchi et al., 2009; Shapiro et
al., 2010; Tonkin et al., 2004). Some of these gene products can interact directly with
ATRX and affect gene expression (Baker et al., 2013; Kernohan et al., 2010; Nan et al.,
2007). Thirdly, there are important roles for proteins with similar functions to ATRX in
skeletogenesis, including SWI/SNF chromatin remodeling, histone modifications, and
genomic integrity (Williams et al., 2010; Young et al., 2005).
It was unexpected that mouse models lacking ATRX in cartilage, bone, or forelimb
mesenchyme displayed relatively minor phenotypes. I propose that the skeletal
phenotypes and dwarfism seen in ATR-X syndrome are more likely due to secondary
effects. These effects were later demonstrated succinctly in a forebrain and pituitaryspecific Atrx-deletion mouse displaying dwarfism, reduced bone mass, and premature
aging (Watson et al., 2013). In this model of ATR-X syndrome, Atrx is deleted in the
embryonic forebrain starting at E8.5. These mice are born small, and before three weeks
of age, display defective and degenerate skeletal phenotypes (Bérubé et al., 2005; Watson
et al., 2013). In addition to significant dwarfism, these animals have shortened growth
plates, reduced bone density, and reduced trabecular number (Watson et al., 2013). It is
crucial to note that these mice lacking ATRX in the forebrain and anterior pituitary have
severe endocrine defects, including defects in the TH/IGF1 axis. In this model of ATRXdeficiency, the skeletal defects are attributed to a secondary, systemic defect where
skeletal development is affected indirectly.
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There are other indirect effects that can influence both skeletal development and growth.
Normal regulation of skeletal growth and mineralisation requires sex steroids, including
androgens and androgen receptors, as well as estrogens and estrogen receptors [Reviewed
in (Callewaert et al., 2010)]. Defects in estrogen sensing in the male mouse leads to
decreased radial and longitudinal bone growth, associated with decreased serum levels of
IGF-I (Vidal et al., 2000). Skeletal defects are seen in androgen-resistant testicular
feminized males, which have low trabecular bone mineral density (Vandenput et al.,
2004). These phenotypes are usually seen post-natally, in late pubertal, or adult stages
(Vidal et al., 2000). This is similar to the forebrain and pituitary conditional Atrx deletion
mouse, which has normal growth plate morphology and trabecular number early in life,
but later develops decreased bone density and other skeletal phenotypes (Watson et al.,
2013). In cases of ATR-X syndrome, individuals frequently present with hypogonadisms
and in some cases even sex reversal (Gibbons et al., 1995; Ion et al., 1996). These
phenotypes are often correlated with delayed or arrested puberty, and manifestation of
growth retardation at the time of the pubertal growth spurt (Gibbons, 2006). In these
cases, levels of sex steroids and their receptors would be affected, and lead to skeletal
defects without a direct effect on gene expression within the cartilage and bone. Thus, it
can be concluded that the most ideal model for studying ATRX in skeletal development
would be a mouse lacking ATRX in the brain and other indirect systems, rather than
removing ATRX directly in the skeleton.
Compared with mouse models of steroid and endocrine defects, mice lacking ATRX in
the cartilage, bone, or forelimb demonstrate slight and limited phenotypes. It can be
predicted that a model combining both direct and indirect skeletal roles of ATRX may
modulate the subtle skeletal phenotypes, such as brachydactyly, towards more severe
defects. My data suggest that some of the skeletal defects are treatable via hormonal
methods. In cases where circulating levels of hormones are affected, patient skeletal size
could be influenced by treatment with growth hormone or drugs to increase endogenous
production of growth hormones.
When considering developmental phenotypes caused by other chromatin-modifying
proteins, such as MECP2 and HDAC4, it is important to consider that ATRX does not
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always affect expression of genes directly. Complexes containing ATRX modulate
genome structure and integrity, and have both tissue-specific and chromosome-specific
functions. ATRX can affect expression of wide-ranging genetic factors, like imprinting
loci and silencing whole chromosomes (Baumann et al., 2009; Kernohan et al., 2010).
Additionally, the role of ATRX can be influenced by other factors including variable
number tandem repeats (VNTRs), which can vary between individuals (Law et al., 2010).
There are very few genotype/phenotype correlations in ATRX syndrome, and even
patients with the same mutation may demonstrate different pathological phenotypes
[Reviewed in (Gibbons, 2006)]; therefore, it is important to consider the inherently
variable nature of ATRX on gene expression when looking at functional phenotypes.

5.3
ATRX and Genome Integrity in the Limb Bud
Mesenchyme
The major objective of this thesis was to determine the role for ATRX in skeletal
development and recapitulate the skeletal defects observed in ATR-X syndrome using a
mouse model. In utilising a tissue-specific conditional knockout model, the role for
ATRX in developing skeletal tissues was identified. Seemingly, the most significant and
specific phenotype seen in these animals did not reveal any new roles for ATRX but
rather confirmed the importance of ATRX in genome integrity and prevention of DNA
damage.
It remains unknown if the cell death observed in conditionally ATRX-deficient forelimb
is a direct consequence of the DNA damage. In other models, mouse Atrx deletion and
loss of ATRX is associated with cell death and hypocellularity (Bérubé et al., 2005; Huh
et al., 2012). In ATRX-deficient neuroprogenitors, γ-H2AX positive DNA damage
accumulates leading to activation of ATM and p53 followed by cell death (Watson et al.,
2013). p53 activation has not been demonstrated in ATRX-deficient forelimbs, but it can
be expected that protein quantification for the ATM-p53 pathway in this tissue would
demonstrate lower activation compared to neuroprogenitors.
The defect in the limbs of these animals was observed only in the distal digit tip and not
the whole limb. The digit tip is the last portion of the limb to develop, with the final
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phalange not being specified until embryonic day 15.5 in the mouse, six days after the
initial development of the limb bud and three days after the metacarpals. Throughout the
development of the limb, the entire structure is laid down by distal outgrowth of
progenitor cells from the progress zone [Reviewed in (Tickle, 2003)]. Proximal limb
bones, as well as the more proximal digit bones such as the metacarpals, differentiate
earlier than those distal; therefore, I expect that distal tissues of the ATRX-deficient limb
bud spend more replicative cycles as mesenchymal cells before finally differentiating into
cartilage. Given the requirement for ATRX observed in mesenchymal cells, but not seen
in cartilage, it can be expected that the most distal portions of the digit would retain the
most DNA damage.
A growing body of evidence has correlated loss of ATRX with both genome instability
and altered DNA damage response (Leung et al., 2013; Lovejoy et al., 2012; Ritchie et
al., 2008; Watson et al., 2013). When ATRX is depleted in HeLa cells, chromatids
demonstrate defective chromosome dynamics and abnormal mitosis (Ritchie et al., 2008).
ATRX-depleted colorectal cancer lines show increased replication stress and have
increased DNA damage following release from thymidine block (Leung et al., 2013).
Defective double-strand break repair and telomere dysfunction have been observed in
ATRX- or DAXX -deficient cancer cell lines (Lovejoy et al., 2012). Endogenous and
replicative DNA damage is also observed in ATRX-deficient neuroprogenitors,
demonstrating an important requirement for ATRX in preventing the accumulation of
DNA damage (Watson et al., 2013). Accumulation of DNA double-strand breaks was
also

observed

in

ATRX-deficient

forelimb

mesenchyme

cells,

but

unlike

neuroprogenitors, these cells do not have reduced viability when challenged with
additional replicative stress. HU treatment of ATRX-null forelimb mesenchyme cells
does not lead to a decrease in viability, suggesting a difference in stress response
compared to other cell types.
In my model of ATRX-deficient forelimb development, I demonstrate that loss of ATRX
leads to increased DNA damage, which associates as a single focus at the nuclear lamina.
Although this damage does not appear to be due to replicative stress, it demonstrates an
increased susceptibility to cell death in the developing digit. This DNA damage is
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significantly increased in mutants compared to controls, and is seen predominantly in the
ATRX-negative cells of mosaic heterozygote females. Although this DNA damage is not
due to replicative stress, the DNA double strand breaks could still activate the p53/ATM
pathway within the forelimb cells. This theory could be examined further through
standard tests of genome stability, and protein analysis for phosphorylation of ATM/ATR
and other checkpoint proteins. Although preliminary studies has shown no difference in
the cell cycle profiles of normal and ATRX-null forelimb cells, the rate of progression
through each part of the cell cycle is unknown. Additionally, the status of the telomeres
in ATRX-deficient forelimbs has not been studied, but telomere FISH may reveal an
increase in telomere dysfunction–induced foci (TIFs). Finally, characterisation of the
single large DNA damage focus in ATRX-depleted cells may reveal characteristic
genome segregation and repair pathways that are activated.
The forelimb deletion model demonstrates a direct correlation between loss of Atrx
expression and increased incidence of DNA damage in forelimb tissue. A similar
mechanism is expected to be at work in the distal hindlimb, and a similar distal phalange
shortening phenotype would be expected if Atrx was deleted in the rear limb bud. My
model did not demonstrate hind limb phenotypes, as expression of the Prx-Cre is limited
in the hindlimb compared to the forelimb during early development (Logan et al., 2002).
My work demonstrates that ATRX is required for normal development of the distal
forelimb, and that skeletal phenotypes observed in ATR-X patients may be due, in part,
to a direct role for ATRX in genomic stability in the developing limb.

5.4

Susceptibility of Skeletal Tissue to DNA Damage

One clear question raised by my study is how some cell types are susceptible to DNA
damage when ATRX is lost, while others are not. Research has shown there is a high
requirement for ATRX for genome stability and survival in the neuronal cells (Watson et
al., 2013), and no requirement for normal growth of cartilage cells (Solomon et al., 2009).
Between these two extremes, proliferative tissues like forelimb mesenchyme have limited
requirement for ATRX, or only a temporal requirement. There are two possible reasons
for this discrepancy; either ATRX is not required for genome stability in certain tissues,
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or these tissues are better equipped to deal with genome instability caused by ATRXdeficiency.
To date, studies have detected ATRX in all mouse tissues examined, and ATRX is
absolutely required during very early embryonic and placental development (Garrick et
al., 2006); however, when ATRX is lost in more differentiated tissues, the requirement
for ATRX appears to be diminished. One possible distinction is that certain tissues,
especially skeletal tissues, are more tolerant to DNA damage and less likely to undergo
p53-dependant cell death observed in other models of ATRX loss (Bagheri-Fam et al.,
2011; Huh et al., 2012; Seah et al., 2008; Solomon et al., 2013). Tissues demonstrating
the highest levels of DNA damage and p53 response when ATRX is lost tend to be
rapidly proliferating (Seah et al., 2008; Watson et al., 2013). In the case of the developing
forelimb, the most affected cells are located in the highly proliferative zone at the distal
tip of the digit which contributes to digit lengthening. These proliferating cells would be
expected to have a sensitivity to replicative stress, but our data demonstrate that HU
treatment in vitro does not reduce viability. This means that forelimb mesenchyme cells
are resistant to specific drugs that induce replication fork stalling, unlike other ATRXdeficient tissues which have shown a sensitivity to this treatment; therefore, loss of
ATRX sensitises certain cell types to conditions that cause DNA damage and viability
loss, but not all cell types.
Certain tissues express proteins that can directly compete with p53 for promoter binding
and prevent cell death (Qian et al., 2012). Senescence marker Dec1 (Differentiated
embryo chondrocyte expressed gene 1) is expressed in response to p53 activation, and
can allow cells to 'choose' between senescence or cell death based on cellular context and
type of DNA damage (Qian et al., 2012). Expression of Dec1 in different cell types may
lead to difference responses to DNA damage. Similar to our study, loss of the singlestranded DNA binding protein OBFC2B in mice leads to delayed growth and skeletal
abnormalities due to accumulation of γ-H2AX

and apoptosis in the pre-cartilage

condensations (Feldhahn et al., 2012). While OBFC2A, a homologue, is required in many
other cell types, OBFC2B is only required in skeletogenesis (Feldhahn et al., 2012).
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Thus, it appears that the skeletal lineage has developed specific methods of dealing with
increased levels of DNA damage during development.
The developmental requirement for ATRX in cell viability varies by cell type. At the
earliest stages of development, ATRX is required for normal mitosis and genome
stability in the ooctye (Baumann et al., 2010; De La Fuente et al., 2004). Complete
ablation of ATRX in the developing embryo is lethal due to defects in the trophectoderm
(Garrick et al., 2006). Loss of ATRX in the developing brain leads to cell death and
hypocellularity, with loss of cells in the dentate gyrus, pyramidal cells of upper cortical
layers, and GABAergic interneurons (Bérubé et al., 2005; Seah et al., 2008). ATRX is
also required in the developing retina, where loss of ATRX is also associated with cell
death of specific neurons. (Medina et al., 2009).
In contrast, some models of ATRX deficiency have mild phenotypes and limited death or
hypocellularity. Mice lacking ATRX in developing muscle demonstrate delayed muscle
growth and deficient muscle regeneration (Huh et al., 2012); however, these animals are
only 20% reduced in size at three weeks of age, and as adults have no significant
difference in body weight (Huh et al., 2012). Similarly, mice lacking ATRX in the
developing cartilage show no change in adult bodyweight, in addition to the absence of
cell population changes in the growth plate or articular cartilage. Mice lacking ATRX in
bone have mild dwarfism, but no defects in patterning, and appear healthy.
I have shown that loss of ATRX in the limb chondrocyte precursors leads to increased
DNA damage, but loss of ATRX following chondrogenic differentiation does not have
the same effect. This is particularly important considering the highly proliferative
cartilage growth plate, which does not appear to have hypocellularity or decreased
proliferation when ATRX is deleted (Solomon et al., 2009); therefore, we can conclude
that skeletal tissues either have reduced susceptibility to DNA damage when ATRX is
lost, or increased capacity to repair damage. In either scenario, loss of ATRX directly in
developing skeletal tissues does not lead to the wide variety of disease phenotypes
associated with ATR-X syndrome.
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5.5
Limitations of Research and Suggestions for
Future Studies
5.5.1

Limitations of the Mouse Model

ATRX is present within the nucleus of normal chondrocytes during development, but
there remains a possibility that there is a compensatory mechanism within the cartilage
when Atrx is deleted. Although there are no direct homologues to Atrx in the mouse
genome, Atrx has homology with members of the Rad54-like subfamily of SNF2 proteins
(Flaus et al., 2006). Deletion of other SNF2 members in cartilage, such as Etl1, have
demonstrated limited penetrance and suggested compensation from other SNF2 family
members (Schoor et al., 1999). By western blot, ATRX shows much higher abundance in
the brain than in cartilage or bone, indicating it may have a reduced requirement in these
tissues (Solomon et al., 2009).
One shortcoming of our model is the assumption that destabilisation of the ATRX RNA
by deleting exon 18 recapitulates the effect of disease-causing mutations in humans. A
truncated isoform of human ATRX, called ATRXt, is produced from a shortened
transcript generated by alternative splicing at exons six and seven, leading to
incorporation of an alternate poly(A) signal (Garrick et al., 2004). This truncated version
is also observed in mouse, producing a ~200 kDa product as opposed to the larger ~280
full-length ATRX (Garrick et al., 2004; Picketts et al., 1998). ATRXt retains the Nterminal ADD domain, but lacks the C-terminal SWI/SNF domain which has been shown
to carry some of the disease-causing mutations (Garrick et al., 2004). Use of the CreLoxP system, with the Atrxflox/flox mouse, generates an animal that lacks full-length
ATRX, but retains normal Atrxt expression (Bérubé et al., 2005). The function of this
shorter transcript remains unknown. Future investigations into the role of ATRX in
skeletal tissue may benefit from generation of new conditional deletion model which
includes loss of the shortened isoform in additional to full-length ATRX.
It is important to note that in many models utilising this conditional deletion model,
severe and sometimes lethal phenotypes are still observed even with the retention of the
shortened isoform (Bérubé et al., 2005; Garrick et al., 2006; Watson et al., 2013).
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Additionally, retention of some ATRX function in mouse may be beneficial in replicating
ATR-X syndrome, as all human cases are hypomorphs and not complete deletions
(Gibbons et al., 2008).
To further elucidate the specific role of ATRX, it may be beneficial to replicate specific
patient mutations and therefore investigate specific genotype/phenotype correlations.
Mouse studies have characterised a milder variant of ATRX-deficiency, in which exon 2
of Atrx was mutated (Nogami et al., 2010). Unlike complete loss-of-function models,
these mice survive and reproduce normally, but demonstrate deficiency in fear
conditioning and dysfunction of αCaMKII and GluR1 (Nogami et al., 2010). Identifying
mutations most frequently associated with skeletal defects, and then replicating these
mutations in a mouse model, would be a more specific tool in studying the direct role for
ATRX in skeletal development.
One particular limitation in the limb-specific deletion model is the specificity of the PrxCre. While the Prx-1 promoter drives cre expression in the developing limb mesenchyme,
it does not drive deletion of floxed genes in the ectoderm including the apical ectodermal
ridge (Nohno et al., 1993); therefore, our model demonstrates the importance of ATRX in
cells of mesenchymal origin, but not those of ectodermal origin. The AER communicates
with the rest of the developing limb, and modulation of Wnt/β–catenin signalling
between the AER and limb mesenchyme leads to digit abnormalities in mice (Villacorte
et al., 2010). To examine the specific role of ATRX in the AER, a different cre line such
as the Keratin 5 (K5) Cre mouse line would be required (Tarutani et al., 1997). A doubleknockout, utilising both the mesenchyme and epithelial deletion of ATRX, would be
expected to demonstrate a more severe phenotype. If ATRX is deleted in the AER, the
expected DNA-damage and potential cell death in the AER would decrease proliferative
signalling to the limb mesenchyme and lead to more severe defects. To study the role of
ATRX in the entire skeleton, it would be useful to delete ATRX in the condensed
mesenchyme as well as perichondrial cells. This model can be achieved using the
Dermo1-cre driver, where cre is expressed in condensed mesodermal tissues leading to
deletion of floxed alleles in both chondrocytes and osteoblasts (Yu et al., 2003). This
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model would provide a combined phenotype of ATRX loss in both bone and
chondrocyte, without the need for two different cre driver lines.

5.5.2

Limitations of Culture Systems

In characterising the animal models in this thesis, various ex-vivo systems were used to
characterise ATRX-deficient cells. Primary chondrocytes from ribs were cultured over
agarose to enrich ATRX-deficient cartilage for Western blot analysis. Primary osteoblasts
were cultured in high density micromass cultures to induce, compare, and quantify
mineralisation between genotypes. Forelimb mesenchymal cells were cultured in
monolayer for drug treatment and viability quantification. In all these cases, there are
specific pitfalls and limitations that must be recognised when interpreting results from
these studies.
When isolating primary animal cells, tissues are subjected to enzymatic digestion which
can alter gene expression (Hayman et al., 2006). In the case of cultured chondrocytes,
culturing over agar is preferred to monolayer culture (Horwitz et al., 1970). Chondrocytes
cultured in monolayer flatten out and become more fibroblast-like, while chondrocytes
cultured over agar retain their phenotype and provide a method to differentiating
chondrocytes from other connective tissue cells (Horwitz et al., 1970). All efforts were
made to use a culture system that would replicate normal chondrocytes and therefore
produce a representative sample of cartilage.
Similarly, cultured osteoblasts from calvaria bone were used to examine ex-vivo
mineralisation of ATRX-deficient osteoblasts. Although primary isolates of osteoblasts
were expanded in monolayer, subsequent long-term culture was conducted in a highdensity micromass system. This model increases the amount of cell-cell contact and is
more physiologically similar to an in vivo model of mineralisation (Gerber et al., 2002).
While this system exists outside of the influence of the endocrine system, it is still
sufficient for studying direct functions of gene loss of osteoblasts.
Treatment with HU was conducted on monolayer cultures of forelimb mesenchyme cells
to determine sensitivity of ATRX-depleted forelimb cells to exogenous replicative stress.
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When examining stress in culture system, it is important to recognise that cell culture
systems experience increased oxidative stress of 'culture shock' and are not always
representative of the cell’s environment in vivo [Reviewed in (Halliwell, 2003)]. Staining
for DNA damage marker γ-H2AX increased with HU treatments in both controls and
mutants, and even without any HU treatment DNA damage was observed in control cells;
however, there was no difference in cell viability between mutant and appropriate
controls. The cell culture model still provides many advantages to an in vivo animal
model, particularly in regard to drug treatments and cell cycle control.

5.5.3

Limitations of the DNA Damage Study and Future Directions

The induction of the DNA damage observed in the forelimb is also poorly understood.
Using HU treatments, it was demonstrated that ATRX-deficient forelimb mesenchyme
cells are not more susceptible to exogenous replicative stress; however, other models of
replicative stress remain to be characterised, including cross-linking with mitromycin C.
There are other forms of stress in the developing limb, which have not been investigated.
Cells exposed to γ-irradiation have induction of double strand breaks in both proliferative
cells and post-mitotic cells, and show activation of the DNA damage response. It is
unknown if there is a requirement for ATRX in repair of exogenous DNA damage in
forelimb tissue, although it is not required for repair of irradiation–induced DSBs in
neuroprogenitors (Watson et al., 2013). Overall, this work suggests that while the role for
ATRX in preventing and reversing DNA damage is not understood, a highly resilient
tissue such as the developing skeleton is not the ideal model for molecular analysis of
ATRX function.
Another topic of future study is the status of the IHH pathway in ATRX-deficient
forelimbs. The digit shortening phenotype observed in these animals resembles
Brachydactyly type A1, which is observed in the BDA mouse harbouring a point
mutation in Ihh (Gao et al., 2009). This mutation abrogates signaling of IHH through its
receptor PTCH and leads to distal digit shortening consistent with the human disorder
(Gao et al., 2009; Guo et al., 2010). Although there is no current role known for ATRX in
regulating members of the IHH pathway, the similarities in the phenotype are
unmistakable. Preliminary unpublished results from our lab have not shown changes in
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the expression of Ihh in ATRX-deficient forelimbs, but a correlation between ATRX and
expression of other brachydactyly related genes remains to be investigated.
One remaining question in this study is the identity of the single DNA damage focus at
the periphery of the nucleus of ATRX-depleted cells. γ-H2AX positive DNA double
strand breaks have been observed in various models of ATRX deletion, but the damage is
observed as speckles throughout the entire nucleus (Leung et al., 2013; Watson et al.,
2013). The forelimb-deletion model is the only model with accumulation of DNA
damage to a single, specific site. It is clear from the presence of the focus in female,
heterozygote cells that the focus cannot be the Y-chromosome; however, the localisation
to the nuclear lamina may offer clues to the identity, and in fact purpose, of this focus.
Recent research in yeast has demonstrated that the nuclear periphery may play a role as a
subcompartment for dangerous DNA elements to be sequestered and possibly repaired
(Gartenberg, 2009). In mammalian cells, the inner nuclear envelope proteins SUN1 and
SUN2 have been shown to be important in DNA damage response and even play a
possible role in nonhomologous end joining repair (Lei et al., 2012). Disregulation of
nuclear envelope proteins has been associated with DNA damage, progeroid, and aging
phenotypes (Capell et al., 2006; Chen et al., 2012). These phenotypes are observed in
models of ATR-X syndrome in which ATRX is deleted in the developing forebrain and
anterior pituitary of mice (Watson et al., 2013). Although it can be predicted that
localisation to the nuclear envelope is an important part of the cell response to ATRX
depletion, the identity of the complex localising to the damaged sequences remains
unknown. Chromatin immunoprecipitations for γ-H2AX on chromatin isolated from
various ATRX-deficient cells may be useful in studying protein-DNA interactions at the
site of DNA damage. Furthermore, chromatin immunoprecipitation techniques in
conjunction with next-generation sequencing (ChIP-Seq) can offer a different perspective
on the DNA-damage focus. By unbiased sequencing of all binding sites of γ-H2AX in
ATRX-deficient cells, it may be possible to identify a common element or site of DNA
breaks.
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5.6

Concluding Remarks

In conclusion, my studies have demonstrated that ATRX has a limited direct role in
skeletal development. Mouse models of ATRX loss in the skeleton reveal that cartilage,
bone, and forelimb mesenchyme are relatively protected from the apoptotic and
hypocellularity phenotypes seen in other ATRX-depletion models.
ATRX is unlikely to have a direct effect on skeletogenesis at the level of the cartilage, as
mice lacking ATRX in this tissue are almost completely physically normal. Genetic
mutations that directly affect important gene signalling in the growth plate lead to
dwarfisms or other skeletal deformities which were not observed in this model. The
deformities observed in ATR-X syndrome are not just in the growth plate; every tissue in
the body is affected. Taken together, it can be predicted that skeletal phenotypes of ATRX syndrome are caused by an indirect effect on the skeleton.
Loss of ATRX in the forelimb confers a brachydactyly phenotype, associated with DNA
damage in limb cells which has been attributed to the role of ATRX in genomic integrity.
In cases where loss of ATRX leads to p53-activated apoptotic cell death, the phenotype
can be partially rescued by deleting p53 in the same tissue (Seah et al., 2008). However,
in some models of tissue-specific loss of ATRX, there can be DNA damage without
activation of cell death, or even loss of ATRX without associated DNA damage. These
studies illustrate an important property of the skeletal system, which is that skeletal
tissues may have reduced susceptibility to apoptosis related to DNA damage compared to
other tissues.
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